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ABSTRACT
Martis, Prithy Caroline, Ph.D., Biomedical Sciences Ph.D. Program, Wright State
University, 2020. RENCA macrobeads inhibit tumor cell growth via EGFR activation and
regulation of MEF2 isoform expression
Tumors are heterogeneous systems, whose growth is influenced by intrinsic properties of
malignant cells, external systemic factors (i.e. immune, neural, endocrine, etc.), and the
dynamic interactions between tumor cells and their microenvironment. Given the inherent
complexity of cancers, combined with the continual evolution of tumors and the
development of treatment resistance, a precision medicine approach may not provide an
optimal clinical response. Exploring a new paradigm that focuses on regulating cancer as
a system may not only control tumor progression but also address the extraordinary
challenges of tumor heterogeneity and disease recurrence in order to improve clinical
outcomes. As a group of discrete, growth-restricted tumor colonies that regulate their own
growth and secrete a large number of tumor-inhibitory signals, RENCA macrobeads
function as a biological-system, providing the opportunity for a systems-therapeutic
approach to cancer management.
Previous work has demonstrated that RENCA macrobeads restrict the growth of various
cancer cells both in vitro as well as in preclinical and clinical studies; however, the
molecular mechanism(s) of this inhibition is unknown. In this study, we demonstrated that
factors secreted by RENCA macrobeads significantly altered the transcript levels of
multiple MEF2 isoforms in targeted tumor cells. Suppression of various MEF2 isoforms
iv

markedly reduced the growth inhibitory effect of RENCA macrobeads and abrogated
macrobead induced S-phase arrest. Importantly, we identified an essential role for the
MEF2D isoform in mediating RENCA macrobead-induced inhibition. In addition, the cellsurface receptor, EGFR, was shown to be involved in the anti-proliferative response to
RENCA macrobeads. Growth inhibition was more robust in cells overexpressing EGFR
and was associated with cell accumulation in S-phase. In cell lines with reduced EGFR
kinase activity or low-levels of cell-surface receptor, we demonstrated that RENCA
macrobeads inhibited growth, although to a lesser degree and exhibited G2/M arrest,
supporting the notion that factors secreted by RENCA macrobeads regulate multiple cell
cycle checkpoints. Lastly, we identified three proteins in conditioned media of RENCA
macrobeads (RTN4, TSP1, TIMP2) that partially contribute to growth regulation of
external tumor cells with functional EGFR activity. Moreover, we identified a novel role
for these proteins in modulating MEF2 activity and regulating MEF2 expression,
particularly the MEF2D isoform.
Overall, these studies support a mechanism by which RENCA macrobeads, at least
partially, regulate tumor growth external to the macrobead. These findings could identify
patients most likely to benefit from RENCA macrobead therapy.
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CHAPTER 1: INTRODUCTION
1.1. Burden and Impact of Cancer
Cancer has long been one of the most devastating and confounding health concerns
worldwide. Accounting for one in every six deaths, cancer is the second leading cause of
global mortality, surpassed only by cardiovascular disease [2, 3]. Based on World Health
Organization (WHO) estimates, in 2018 alone, there were 18.1 million new cases of cancer
diagnosed and more than 9.6 million deaths [3, 4]. To add to the existing burden, worldwide
incidence of cancer and death rates are forecasted to rise rapidly as populations grow, age,
and adopt lifestyles that increase cancer risk [4].

1.2. Tumor biology
Cancer is not a singular, specific disease but a group of more than 150 disease processes
that can involve any tissue in the body. Rather than responding appropriately to signals that
control normal cell behavior, defects in the regulatory circuits of cancerous cells allows for
continual proliferation, dissemination, invasion into adjacent tissues and colonization of
abnormal cells at distant sites, termed metastases [5].

Based on the somatic mutation theory (SMT), initiation and progression of cancers hinge
on the acquisition of driver mutations of key genes, related RNA and protein products that
activate oncogenic pathways [6, 7]. These molecules typically coordinate signaling to
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regulate the balance of proliferation, survival and apoptosis in normal quiescent cells [8,
9]. However, the mutant phenotype confers selective growth and survival advantages that
allow transformed cells to expand and achieve clonal dominance [10], eventually forming
a tumor mass.

An alternative theory of tumorigenesis, the tissue organization field theory (TOFT), posits
that cancer is a tissue-based disease wherein proliferation is the default state of all cells
[11]. In this model, carcinogens act to disrupt the reciprocal interactions between
parenchymal and stromal components of tissues [12-14]. Disruption of normal tissue
architecture alters the cells’ ability to appropriately recognize and respond to positional and
contextual cues, resulting in excessive proliferation (hyperplasia), disorganization of
epithelia with abnormal histology (dysplasia) and cell transformation (metaplasia).
Ultimately, epithelial cells unable to restrain their intrinsic proliferative properties form a
tumor mass [12].

Tumors are classified according to anatomical site, histopathological and morphological
profiles, as well as stage [15]. Tumor stage, a critical determinant of prognosis, is based on
the TNM system developed by Pierre Denoix and the Union for International Cancer
Control (UICC) [16]. In the TNM classification, the T category describes the extent of the
primary tumors, by size, depth of invasion or invasion of adjacent structures; the N
categorizes the absence or extent of regional lymph node involvement; and the M category
indicates the absence or presence of distant metastasis [16, 17]. For instance, pathological
evaluation of a tumor identified in the sigmoid colon that has invaded the submucosa with
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no lymph node involvement or distant metastasis is classified as T1N0M0 (Stage I
colorectal cancer). This combination of TNM categories, since its implementation in the
1940’s, has described cancer diagnoses and guided the approach to treatment [16]. In the
genomic era, the influx of complex multi-omics data has captured a new spectrum of
biological diversity, providing novel diagnostic and personalized treatment targets [18, 19].

1.3. Cancer treatments
The ultimate goal of treatment programs has been to cure cancer using a multidisciplinary
approach – combining surgery, radiotherapy and chemotherapy – directed at the primary
tumor and potential metastases [20]. In recent years, molecular-targeted therapy and
immunotherapy have expanded the cancer treatment arsenal in an effort to improve tumor
control [21-23].

Surgery: As the earliest form of cancer therapy, surgery remains the mainstay for the
treatment of most solid tumors. Surgery is most effective for localized tumors with welldefined borders. This is accomplished by resection of lesions encompassed by a continuous
margin of healthy tissue and removal of associated lymph nodes [24, 25]. As such, surgery
alone has a limited role in disease management in patients with advanced disease or in the
presence of distant metastases.

Radiotherapy: Radiation therapy uses high-energy particles (e.g., x-rays, gamma rays or
proton beams) guided by computed tomography to damage and destroy cancer cells [2628]. When used to treat localized cancers, radiation therapy can provide a complete
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response but only offers supportive care in advanced or disseminated disease [26, 28].
Neoadjuvant radiotherapy is frequently used to reduce tumor burden prior to surgery or in
cases of incomplete surgical resection, postoperatively, to tackle residual disease and
minimize tumor recurrence [29]. However, one of the fundamental problems of radiation
oncology is tumor resistance to radiation doses which cause an acceptable degree of normal
tissue toxicity, leading to locoregional control failure and disease progression [30, 31].

Chemotherapy: An aggressive form of chemical drug therapy, chemotherapy targets
rapidly proliferating cells in the body [32, 33]. Chemotherapeutic drugs, classified
according to their chemical composition and function, halt cell division. These include (1)
alkylating agents, such as cyclophosamide and platinum based drugs, that intercalate with
DNA resulting in DNA cross-links and single-strand DNA breaks [34, 35]; (2)
antimetabolites, such as 5-fluorouracil, gemcitabine and methotrexate, which are structural
analogs of folic acid, purines or pyrimidines that interfere with nucleic acid synthesis [36,
37]; (3) anthracyclines, such as doxorubicin, that inhibit the activity of DNA replication
enzymes [38-40]; (4) plant alkaloids, such as taxanes and vinorelbine, that interfere with
microtubule dynamics [41, 42] and (5) corticosteroids, such as prednisone and
dexamethasone, that induce DNA fragmentation at high doses [43, 44]. These drugs disrupt
core cellular processes to achieve systemic growth control of malignant cells. As such,
chemotherapy remains the standard treatment modality for many advanced cancers,
although it is not always curative as a stand-alone protocol. Often used in conjunction with
surgery, chemotherapy acts to eradicate tumor cells that have already metastasized or in
addition to radiotherapy, to sensitize malignant cells and enhance the cytotoxic effect of
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radiation [32, 33]. However, chemotherapeutic drugs indiscriminately destroy replicating
cells, normal (e.g., hair follicles, bone marrow, gastrointestinal epithelium, and immune)
and cancerous alike, causing systemic toxicity and long-term health issues that adversely
affect a patients’ quality of life. Despite data supporting the survival benefit of
chemotherapy, chemoresistance remains a major obstacle to successful treatment, leading
to disease recurrence and metastases [45].

Targeted Therapy: Targeted therapies block the proliferation of cancer cells by
interfering with specific molecules required for tumor development and growth. Although
these molecules may be present in normal tissues, they are often mutated or overexpressed
in tumors, representing promising therapeutic targets in the management of cancer [46, 47].
Pathways associated with these molecules can be inhibited at multiple levels: (1)
neutralizing ligands; (2) occluding receptor-binding sites; (3) blocking intracellular
receptor signaling; or (4) interfering with intracellular downstream molecules. Monoclonal
antibodies and small molecule inhibitors are the two main approaches of specific molecular
targeting available for use in clinical practice [48]. Monoclonal antibodies, which are
usually large (~150 kDa) and water soluble, target extracellular components of these
pathways while small molecule cancer drugs, because of their size (£500 Da), can
translocate through the plasma membrane and affect intracellular processes that play a key
role in transducing downstream cell growth signaling [49-52]. Despite an explosion of
information about the biological basis of cancer, identifying actionable alterations that
drive cancer progression and thus define molecular targets remains a challenge for
researchers [53]. Moreover, targeted therapies are only producing appreciable therapeutic
5

responses in a fraction of patients of a particular type, and even within a specific subtype.
Some tumors, while envisioned to respond, instead continue to grow and progress to states
of heightened malignancy [54-56].

Immunotherapy: Immunotherapies aim to exploit the therapeutic potential of tumorspecific antibodies and cellular immune effector mechanisms to restore the anti-tumor
response of a patient’s suppressed immune system [57, 58]. Immunotherapeutic agents
currently in development, such as monoclonal antibodies, cancer vaccines, chimeric
antigen receptor (CAR)-T-cell therapies and immune checkpoint inhibitors, are designed
to (1) block negative regulatory signals that promote immune evasion of tumors; and (2)
stimulate immunogenic pathways. Despite the successful application of cancer
immunotherapies across a broad range of cancers, durable responses are only observed in
a minority of patients with advanced disease [59, 60]. Besides, intravenous administration
of immunotherapies believed to be essential for systematically regulating the immune
response against disseminated tumors often result in debilitating toxicities [61-63]. These
limitations, along with an incomplete understanding of the intricacies of immune regulation
in cancer, the lack of predictive biomarkers, and the development of resistance to
immunotherapies present formidable obstacles to treatment [64].

1.4. Tumor heterogeneity: A hurdle for cancer treatment
Tumor heterogeneity represents one of the greatest challenges to effective cancer
treatment. The nonuniformity of cancer has long been appreciated, reflected most visibly
in the widely divergent responses of histologically similar tumors to a given treatment
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(interpatient heterogeneity) [65]. The extent of tumor heterogeneity is only beginning to be
realized with the advent of novel sequencing technologies. The coexistence of different
cancer cell subpopulations within a single tumor, described as intratumor heterogeneity
[66-68], generates substantial complexity in cancer. Intratumor heterogeneity appears
through different stages of tumor progression (temporal), varied locations within the tumor
(spatial) as well as in response to cancer therapies [69-72]. This non-homogeneous mass
of cells displays genetic, epigenetic and phenotypic diversity [73-76]. Illustrating this
astounding heterogeneity, in one analysis of a single hepatocellular tumor, approximately
the size of a golf ball, a sampling of 286 regions from a single slice of the tumor revealed
more than 100 million coding region mutations [77]. Adding to that complexity are the
increasing differences between primary tumors and metastatic foci (intrapatient
heterogeneity). Metastatic lesions at secondary sites can arise from different cell
populations within a single primary tumor, contributing to heterogeneity among
metastases, and since metastatic lesions can acquire new mutations and evolve
independently, variability within metastases can also exist [78]. Furthermore, the cellular
environment surrounding a tumor, the tumor microenvironment (TME), composed of
stromal (e.g., fibroblasts, adipocytes, endothelial cells etc.) and immune cells can be
another source of heterogeneity. Mediated by chemokines, angiogenic factors, and
cytokines, crosstalk between the tumor and non-malignant cells can alter both tumor and
normal cell behavior, thereby influencing clinical outcomes [79, 80]. Overall, this
measured heterogeneity reflects only a static snapshot of the cells within a continually
evolving tumor and its environment. Ultimately, what emerges is a view of cancer as an
extraordinarily diverse group of neoplastic cells in the context of a complex tumor
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microenvironment that functions at various spatial and temporal scales, cooperating as a
highly dynamic organ system. It is therefore not surprising that universally applied
treatments, even in combination, lead to inconsistent therapeutic responses, residual or
refractory disease, tumor recurrence and eventually treatment failure [81].

1.5. RENCA macrobead therapy
The chaotic, adaptive nature of cancer constitutes a compelling reason to explore a new
paradigm that focuses on regulating cancer as a system. This approach requires shifting
from a reductionistic framework that seeks to block specific pathways and destroy aberrant
cells to a systems biological approach aimed at simultaneously controlling multiple levels
of dysfunction. In other ‘system’ diseases, such as diabetes or cardiovascular disease,
where multiple systems (e.g., endocrine, immune, neural and circulatory systems) interact
to influence pathogenesis and prognosis, clinicians have demonstrated tremendous success
in disease management by regulating various components of such systems to function in a
normal physiological manner. Effectively treated as a lifelong condition, medications serve
to control disease progression and improve quality of life. Similar to diabetes and
cardiovascular disease, cancer may be able to be treated as a chronic, systems disease,
wherein the growth and lifespan of cancer cells can be continually regulated, allowing
patients to live with the disease. Chronic, according to the CDC, means controlled but not
cured [82]. Although this terminology is as relevant for cancer as it is for heart disease or
diabetes, current cancer treatment protocols are not sustainable – high toxicity and drugrelated complications associated with existing therapies preclude long-term use. As a
solution to the avoidance of such toxicities, a biological-based system, in which normal
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physiology is continuously regulated, may provide a therapy that is capable of inhibiting
cancer cell proliferation and thereby long-term growth control leading to tumor regression.
As a biocompatible, cell-system anti-cancer therapy, RENCA macrobeads meet these
requirements [1, 83-87].

What are RENCA macrobeads? RENCA macrobeads are mouse renal adenocarcinoma
cells encapsulated in a double layer of agarose (6-8 mm in diameter) [1] (Figure 1A). Upon
encapsulation, cells are uniformly distributed throughout the inner coat as single cells or
small cell clusters. Over multiple weeks, cells proliferate, forming ellipsoid-shaped tumor
colonies (Figure 1B). These colonies recapitulate many of the basic three-dimensional
structures of tumors, including a multicellular framework, centralized necrosis, and
proliferation gradients. In addition, RENCA macrobeads exhibit comparable growth
kinetics as in vivo tumors [88-90]. Characterized by an exponential growth phase when
macrobeads are young and colonies are small, growth decelerates as colonies within the
macrobead enlarge [1], similar to proliferation plateaus experienced by large tumors in
vivo [88, 90]. Colonies that have reached a maximal size in mature RENCA macrobeads
remain stable indefinitely but exhibit continuous cell turnover, with cells positive for
molecular markers of proliferation (e.g., PCNA, BrdU) or apoptosis (e.g., p27, caspase-3)
[1]. The double-layer architecture of the agarose hydrogel provides key elements to
RENCA macrobead structure, function and stability. The higher agarose concentration of
the outer coat contributes to structural integrity as well as prevents tumor cell outgrowth
from the macrobead. This structural feature also provides a physical barrier to protect
encapsulated cells from direct interaction with host immune cells while the porous
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A.

Mouse kidney cancer
tumor colonies

Tumor inhibitory proteins
& other factors

Outer coat
(4.5% agarose)

Nutrients

Inner coat
(0.8% agarose)

Diameter: 6-8 mm

B.

Day 1

Day 7

Week 4

Week 12

Figure 1: The RENCA macrobead. (A) Photograph of a RENCA macrobead stained
with 0.33% (w/v) neutral red. RENCA macrobeads are an agarose matrix containing
mouse renal adenocarcinoma cells. Macrobeads consist of two spherical layers of
agarose with mouse RENCA cells contained within the inner coat. Each macrobead has
a diameter of 6-8 mm. (B) Natural history of the RENCA macrobead. Macroscopic and
microscopic appearances of day 1 through Wk. 12 RENCA macrobeads. Top,
macroscopic photographs of RENCA macrobeads taken during an MTT assay
demonstrate metabolically active cells and colonies (purple color) on day 1, Wk. 4, and
Wk. 12 with a significant loss of metabolically active cells on day 7. Bottom,
micrographs of H&E-stained sections of RENCA macrobeads demonstrating
significant loss of day 1 encapsulated viable cells by day 7 in which two distinct types
of cells survive (insets day 7) that produce ellipsoid tumor colonies that enlarge over
time reaching a final size around 12 weeks of age. Arrows indicate viable cells and
arrowheads denote cell debris. Scale bars for large micrographs are 50 µm and for insets
at day 7 are 10 µm [1].
10

hydrogel allows sustained release of signals (e.g., peptides, proteins, exosomes, various
forms of RNA) from growth-restricted tumor colonies [1, 85].

Safety and efficacy of RENCA macrobead therapy: In vitro studies have indicated that
RENCA macrobeads (or macrobead conditioned media) inhibit the growth of various
cancer cell lines, including mouse renal carcinoma (RENCA), osteosarcoma (K7M2),
human prostate (DU145), bladder (J82) and colorectal cancer (HCT116) [85]. The antiproliferative effect is dependent on the age of RENCA macrobeads. At early stages of
development, young RENCA macrobeads (2-3 weeks post encapsulation) that have not
formed tumor colonies do not inhibit the growth of external tumor cells. As macrobeads
mature, their inhibitory capacity increases to approximately 50% at 24 weeks postencapsulation and remains consistent for at least two years. Moreover, the observed
inhibition is neither species nor tumor-type specific, although distinct cell lines are
differentially inhibited by RENCA macrobead treatment [85].

Preclinical studies indicate that RENCA macrobeads are effective in reducing tumor
burden in orthotopic murine models [85]. Mice with RENCA cells placed under the renal
capsule had significantly smaller tumors (30-60%) following implantation of RENCA
macrobeads into the peritoneal cavity as compared to control mice treated with empty
macrobeads (double layer of agarose without cells). In companion cats and dogs with endstage, spontaneous cancers, RENCA macrobead treatment also showed evidence of tumor
growth control [85]. In cases of gastrointestinal lymphoma and mammary carcinoma,
RENCA macrobead treatment prolonged survival following multiple implants. Maximum
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growth control was observed in canines with prostatic adenocarcinoma. These dogs
survived a median of 177 days from diagnosis as compared with no treatment (21-30 days),
partial prostatectomy (<14 days for 7 out of 10 dogs), or total prostatectomy (<50 days, n
= 10) [85]. Moreover, a majority of the animals demonstrated positive quality of life
indicators, including an increased appetite, weight gain, higher activity and improved wellbeing [85].

Clinical data also supports the safety and efficacy of RENCA macrobead therapy in
multiple tumor types. These patients are classified with Stage IV disease (metastatic
cancer) and had failed all available, approved therapies prior to enrollment in RENCA
macrobead trials [83, 84, 86, 87]. Only mild and transient treatment-related adverse events
were observed in Phase I clinical trials which included patients with advanced, refractory
peritoneal and thoracic cancers [87]. A decrease in the level of circulating tumor markers,
carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19-9), was noted in
approximately 70% of treated patients regardless of cancer type. In addition, PET-CT
measurements of tumor burden indicated suppression of metabolic activity and induction
of peripheral necrosis [87]. Results from open-label Phase II clinical trials investigating
RENCA macrobeads in patients with metastatic, treatment-resistant colorectal cancer
(mCRC) also demonstrated decreased CEA and CA19-9 levels, stable to decreased tumor
volumes, reduced uptake of 18F-FDG, and stable levels of lactate dehydrogenase (LDH) in
responders (R) as compared to non-responders (NR) [83, 84, 86]. Response to RENCA
macrobead therapy correlated with increased overall survival (OS) (R mean OS = 10.76
months; NR mean OS = 4.9 months) and good quality of life scores [86]. While being safe
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and effective in a wide variety of cancers, this data indicates that RENCA macrobead
therapy offers a broad-spectrum treatment approach that provides a genuine benefit in
clinical outcomes for cancer patients.

Exploring RENCA macrobead mechanism of action: RENCA macrobeads inhibit cell
proliferation by inducing apoptosis following cell accumulation in S-phase [85]. Following
culture in replete media (concentrated RENCA macrobead conditioned media brought up
in fresh media), time-lapse microscopy studies indicated that fewer target tumor cells enter
mitosis. Of the cells that entered mitosis, a significantly lower fraction (56%) successfully
completed cell division while nearly all RENCA cells (>99%) in fresh media transitioned
through mitosis. Mitotic failure resulted in cell death [85]. Culture in replete media also
caused a delay in cell cycle time as compared to fresh media (30h vs. 24h) and induced Sphase arrest [85]. Gene expression profiles of target tumor cells exposed to replete media
identified a prevalence of S-phase checkpoint genes with significant upregulation of
transcripts associated with the DNA damage response (e.g., Gadd45, CHOP, Gas5,
homologs of Chk2, etc.) [85]. Although this data suggests that RENCA macrobeads inhibit
the growth of RENCA cells by inducing cell cycle checkpoint delays with upregulation of
DNA damage surveillance and repair programs followed by abortion of the cell cycle and
death via apoptosis, the molecular mechanism(s) of this inhibition remains unknown.

Communication between RENCA macrobeads and physically distant tumor cells is likely
mediated through diverse mechanisms. As mediators of essential cellular processes,
proteins facilitate intercellular communication, offering one avenue of research. Mass
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spectrometry studies performed in our laboratory demonstrated that RENCA macrobeads
release more than 700 proteins into their environment, many of which limit cancer cells’
proliferative and survival advantages [85]. Given the large number of proteins secreted by
RENCA macrobeads, predicting relevant signaling pathways involved in macrobeadmediated inhibition is challenging. Since extracellular stimuli regulate gene expression by
controlling the activity of transcription factors, we utilized a 45-pathway reporter array to
identify signaling pathway-associated transcriptional regulators responsive to factors
secreted by RENCA macrobeads [91]. This study found increased activity of the
transcription factor myocyte-enhancer factor 2 (MEF2) in target tumor cells in parallel to
the antiproliferative effect of RENCA macrobeads.

Myocyte-enhancer factor 2
MEF2 proteins belong to the MADS (minichromosome maintenance genes (MCM1) –
agamous (AG) – deficiens (DEFA) – serum response factor (SRF)) family of transcription
factors [92, 93]. In vertebrates, MEF2 proteins are encoded by four genes – namely,
MEF2A, MEF2B, MEF2C, and MEF2D which are expressed in distinct but overlapping
patterns in tissues [94]. All MEF2 proteins share a highly conserved MADS-box and MEF2
domain in the N-terminus that mediate dimerization, DNA binding and co-factor
interactions [95-97]. In contrast, the carboxy-terminus is structurally diverse amongst
isoforms and features the transactivation domain which is subject to alternative splicing
and covalent modifications, such as phosphorylation, acetylation, and sumoylation [95, 98,
99]. MEF2 responds to signals originating from multiple cell surface receptors, including
G-protein coupled receptors [100], epidermal growth factor receptor (EGFR) [101-103],
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the lipopolysaccharide receptor [104], as well as others. MEF2 proteins bind to the
consensus DNA sequence (C/T)TA(A/T)4TA(G/A) as homo- or heterodimers, thereby
integrating extracellular signals into cellular processes by regulating a specific set of genes
[95, 105-107].

Initially identified as key components of muscle cell differentiation, the activities of MEF2
are just beginning to be recognized in cancers [108-110]. However, their involvement is
controversial – as MEF2 transcription factors interact with distinct co-factors and can be
influenced by post-translational modifications, they have been described to function both
as transcriptional activators or repressors in selective contexts and tissues.

Altered MEF2A expression associated with a proliferative phenotype in some cancers
suggest a tumorigenic role for this isoform. In pancreatic cancer, a frequent MEF2A single
nucleotide polymorphism (SNP) (Y105C) was considered a negative prognostic marker
[111]. MEF2A protein levels are also frequently upregulated together with MEF2C in
hepatocellular carcinoma as compared to levels in normal or cirrhotic livers [112]. Similar
data is available for gastric cancer wherein 10% of patients are characterized by a
significant increase in MEF2A mRNA. In gastric cancer cells, p38/MAPK signaling can
activate MEF2A to promote glycolysis and proliferation [113]. In the same cells, MEF2A
is described to have a tumor suppressive role. Activated MEF2A induced G0/G1 arrest and
inhibited proliferation of NCI-N87 cells by inducing expression of p21 and decreasing
cyclin D1 [114].
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From a phylogenetic perspective, MEF2B is the most divergent of the MEF2 proteins
[115]. MEF2B is amplified in a fraction of ovarian carcinomas, uterine cancers,
adrenocortical carcinomas and esophageal cancers indicating that this isoform may act as
an oncogene in these tumors [116-118]. Supporting a malignant phenotype, ectopically
expressed MEF2B in HEK293A cells promoted cell migration and increased expression of
the anti-apoptotic protein, Bcl2 [119]. Among MEF2B target genes is BCL6, an oncogene
identified in B-cell lymphomas that influences expression of genes involved in the DNA
damage response, cell cycle control and differentiation [120, 121]. As such, knockdown of
MEF2B is associated with decreased cell cycle progression linked to G1 arrest [122] and
has also been shown to diminish expression of DNA damage induced apoptosis suppressor
(DDIAS), an anti-apoptotic protein that promotes cancer cell survival [123]. Moreover,
MEF2B heterozygous somatic mutations were described in a small percentage of
lymphomas, including diffuse large B-cell lymphomas (DLBCL), follicular lymphomas
and mantle cell lymphomas [124-127]. In cells modeling common hotspot mutations
identified in DLBCL, MEF2B transcriptional activity was increased and promoted cell
migration and survival [119].

A role of MEF2C as an oncogene was initially suggested in leukemic cells. Increased
MEF2C expression is characteristic of immature T-cell acute lymphoblastic leukemia
[128]. Furthermore, MEF2C was described to act as a cooperating oncogene in
combination with Irf8 deficiency [129] or Sox4 activation [130] to accelerate myeloid
leukemia development. Myeloid leukemias demonstrated increased MEF2C expression
and required elevated MEF2C levels to induce colony formation [131]. MEF2C also
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promoted migration and invasion of leukemic cells [129]. Additional data supports a prooncogenic function of MEF2C in some solid tumors. In colorectal cancer, MEF2C levels
were increased during disease progression [132]. MEF2C expression was also associated
with tumor invasion of breast cancer [133]. Although MEF2C is overexpressed in
hepatocellular carcinoma (HCC) [112, 134, 135], this isoform displays both oncogenic and
tumor suppressive properties. MEF2C mediated VEGF-induced angiogenesis and
promoted HCC invasion through p38/MAPK and PKC signaling while inhibiting cancer
cell proliferation by blocking b-catenin nuclear translocation [135]. Supporting a tumor
suppressive role, overexpression of MEF2C in rhabdomyosarcoma cells abrogated
proliferation and anchorage-independent growth [136].

Early evidence for the involvement of MEF2D in tumorigenesis came from studies of
childhood acute lymphoblastic leukemia (ALL). In ALL, chromosomal translocations
involving MEF2D, although rare, were associated with increased proliferation and a worse
prognosis [137, 138]. Several other reports have also supported an oncogenic role for
MEF2D in different solid tumor models. High levels of MEF2D in HCC are associated
with poor prognosis [139]. In these cells, MEF2D silencing limited proliferation and
abolished tumorigenicity in mouse xenograft models [139]. In addition, elevated
expression of MEF2D has been observed in lung cancer [140], gastric cancer [141], and
pancreatic cancer models [142]. However, MEF2D has been described to have antiproliferative functions in rhabdomyosarcomas, low grade uterine leiomyosarcomas and
breast cancers [143-145]. Expression of exogenous MEF2D in rhabdomyosarcoma cell
lines promoted differentiation, inhibited cell proliferation and limited cell migration [145].
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In a model of rhabdomyosarcoma, MEF2D repression was linked to genes regulating cell
cycle progression, namely GADD45 and CDKN1A [146].

Studies in non-cancerous cells have also highlighted a role of MEF2 in cell cycle
regulation. In multiple cell types, including myoblasts, fibroblasts and mammary epithelial
cells, levels of specific MEF2 isoforms have been described to fluctuate during the cell
cycle. In G1, S, and early G2 phases, MEF2C levels are high but sharply decline as cells
progress from G2 to M phase [147]. Likewise, MEF2D levels remain relatively low
following S phase through the G2/M transition and increase as cells exit the cell cycle [144,
148]. Stabilization of MEF2C inhibits nuclear accumulation of Cyclin B1 and impairs
progression through mitosis [147]. Unscheduled MEF2 transcription during the cell cycle
induces p21, a MEF2C and -D target gene that prompts growth arrest and reduces cell
proliferation [148]. While no direct evidence for MEF2A expression during cell cycle
progression has been reported, vascular myocytes display increased levels of MEF2A when
induced to proliferate in serum [149]. Inhibition of MEF2A induces a G1 block followed
by forced cell cycle reentry [150, 151] while increased levels of constitutively active
MEF2A positively correlates with CHOP expression [152]. This protein participates in ER
stress-induced and mitochondria-mediated apoptosis [153]. Accordingly, transcriptional
regulation of homologous members of the MEF2 family could be a mechanism by which
RENCA macrobeads coordinate cell cycle programs to mediate growth inhibition.

Transcriptional control can be modulated by signal transmission from the cell surface to
the nucleus. Receptors span the interface of cells, facilitating communication between the

18

extracellular and intracellular environments. To gain insight into which cell surface
receptors transduce RENCA macrobead protein signals into intracellular responses, we
assessed the effect of RENCA macrobead conditioned media on the activity of a panel of
transmembrane receptors, comparing young vs. mature RENCA macrobeads (none vs.
partial inhibition). In our preliminary studies, total and phosphorylated levels of EGFR
positively correlated with increased growth inhibition of RENCA cells.

Epidermal growth factor receptor
EGFR, also known as ErbB1/HER1, is a N-linked glycosylated membrane bound receptor
tyrosine kinase (RTK) that belongs to the ErbB receptor family [154]. EGFR was originally
characterized as an oncogene, due to its homology to v-ErbB, a retroviral protein that
enables avian erythroblastosis virus to transform chicken erythroblasts [155]. Subsequent
research reporting EGFR gene amplification and hyperactivity in multiple malignancies
cemented EGFR signaling as a driver of oncogenesis [156, 157]. As such, pharmacological
inhibition of EGFR has been a topic of intense research for several decades. Yet, other
studies have featured a paradoxical growth inhibitory property of EGFR activation [158163]. For example, multiple cell lines, such as epidermoid carcinoma (A431), non-small
cell lung carcinoma (A549), and basal-like breast cancer cells (MDA-MB-468), undergo
apoptosis following exposure to high doses of EGF [164-172]. Data has shown that the
observed apoptosis requires an active tyrosine kinase [167, 168]. Decreasing EGFR
phosphorylation with a tyrosine kinase inhibitor increased cell viability compared to EGF
treated cells [167].
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However, there is no consensus as to the mechanism by which EGFR activation limits cell
growth and promotes apoptosis. Astuti et al. demonstrated that EGF stimulates the MAPK
pathway and blocks exit from G2 checkpoint arrest by destabilizing cdc25, the phosphatase
responsible for activating CDKs [173]. EGF has also been shown to promote de novo
synthesis of the cyclin-dependent kinase inhibitor, p21 via activation of Stat1/Stat3.
Depending on the study, Stat-mediated p21 expression delays progression through G2/M
phase [174-176] or induces apoptosis [177, 178]. Subsequent research has provided
evidence that Etk/Bmx, a member of the Tec family of tyrosine kinases, potentiated EGFinduced Stat1 activation [179]. Other groups have linked EGFR-mediated cellular toxicity
to intracellular Ca2+ overload. In breast cancer cells, elevated cytoplasmic Ca2+ levels
triggered by EGFR activation contributes to oxidative stress and mitochondria-mediated
apoptosis via p38/JNK activation [180]. This is associated with increased expression of the
pro-apoptotic proteins CHOP and Bim [180]. A similar effect was observed in xenografted
NSCLC tumors treated with EGF. EGF-injected A549 tumors were significantly smaller
than controls and exhibited reduced proliferation rates as evidenced by decreased Ki67+
cells [172]. Moreover, markers of mitochondrial dysfunction (e.g., Rac1, p22phox, Ref-1)
were higher in tumor tissues from EGF-treated mice as compared to PBS-treated controls
[172].

Synthesized as a 1210 residue precursor that is cleaved at the N-terminus to form a 1186
residue mature transmembrane protein [154], EGFR consists of an extracellular ligandbinding region, a single membrane-spanning a-helix and a cytoplasmic tyrosine kinase Cterminal domain [181]. EGFR functions to sense and respond to extracellular signals.
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Binding of soluble ligands to the EGFR ectodomain promotes homo- or heterodimer
formation, with a stoichiometry of 2:2 ligand:receptor [182, 183], activation of the kinase
domain and autophosphorylation of multiple tyrosine residues in the cytoplasmic tail [184186]. In addition, ligand-receptor interactions induce EGFR internalization and
intracellular sorting to vesicular transport systems that recycle receptors to the cell surface
or direct internalized EGFR to lysosomes for degradation [187-190]. EGFR binds at least
seven different activating ligands: EGF, transforming growth factor-a (TGFa),
amphiregulin (ARG), betacellulin (BTC), heparin-binding EGF-like growth factor (HBEGF), epiregulin (EPR), and epigen (EGN) [191]. EGFR activation initiates multiple
intracellular signaling pathways, including the MAPK, PI3K, SRC, PLC-g, JNK, and JAKSTAT pathways [192-194]. These pathways, which are estimated to encompass 122
proteins, are interlinked at the molecular level [195]. As such, the activation of EGFR
stimulates a complex, integrated signaling network, producing a diverse repertoire of
biological responses [196]. Adding to this signaling diversity, EGF-like sequences present
in other proteins can also activate EGFR [197-199]. These EGF motif-containing ligands
can directly bind the receptor or transactivate EGFR through crosstalk with heterologous
receptors [200-202]. For example, reticulon-4 (RTN4), thrombospondin-1 (TSP1), and
tissue inhibitor of metalloproteinase-2 (TIMP2) have been shown to regulate EGFR
activity. These proteins, identified in conditioned media of RENCA macrobeads at
different stages of development, have been described to suppress tumor growth in diverse
contexts and may participate in RENCA macrobead-mediated growth inhibition of target
tumor cells.
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Reticulon-4 (RTN4)
RTN4 is a highly conserved member of the reticulon family of proteins predominantly
associated with the smooth endoplasmic reticulum (ER) [203-205]. RTN4 functions to
establish ER membrane curvature [206-208] and vesicle formation [203]. In addition to
defining the architecture of lipid membranes, the best studied function of RTN4 is
inhibiting neurite outgrowth and axonal regeneration following spinal cord injury [209216]. Evidence also points to the involvement of RTN4 in the progression of glioma [217]
and prostate cancer cell lines [218]. In these studies, RTN4 overexpression slowed
proliferation and induced cell cycle arrest. In addition, recent studies have reported a role
for RTN4 in inducing apoptosis in neural systems [219-221], atherosclerotic models [222]
and multiple cancer cell lines [223]. In Hela cells, RTN4 has been shown to contribute to
endoplasmic stress-mediated apoptosis triggered by depletion of ER Ca2+ stores and
upregulation of pro-apoptotic transcription factors [224]. Stable overexpression of RTN4
in a neuroblastoma model upregulated activated caspase-3 and Bax, a pro-apoptotic
member of the Bcl-2 family that promotes loss of mitochondrial membrane potential [225].
RTN4 has also been shown to associate with the anti-apoptotic proteins Bcl-2 and Bcl-XL
and alter their sub-cellular localization, thereby reducing their anti-apoptotic activity [226].

RTN4 preferentially interacts with the RTN4 receptor (RTN4R) [227]. However, RTN4
receptors lack a transmembrane and signaling domain, thereby requiring a co-receptor or
signal transducer to transmit intracellular messages. The transmembrane protein LINGO1, the neurotrophin receptor p75, and the orphan tumor necrosis factor family member
TAJ/TROY have all been shown to bind RTN4R and facilitate inhibition of neurite
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outgrowth [228-233]. Epidermal growth factor receptor acts a signal transducer for
RTN4R. While EGFR does not directly bind RTN4R, the kinase activity of EGFR has been
shown to be required for the inhibitory action of RTN4 in neuronal cultures [234].

Thrombospondin-1 (TSP1)
TSP1 is an extracellular matrix molecule that belongs to a family of homologous
glycoproteins with diverse effects on cell behavior [235, 236]. Disruption of the thbs1 gene
in mice results in craniofacial dysmorphism, spinal deformity, exaggerated inflammatory
responses, and altered rates of wound healing and tissue remodeling in various injury
models [237-240]. The role of TSP1 in cancer growth control is controversial, as it exerts
complex and sometimes opposing effects. For example, TSP1 is overexpressed by invasive
and metastatic melanoma cells, in which it actively contributes to epithelial-tomesenchymal transition [241, 242]. On the contrary, suppression of THBS1 expression in
metastatic clones of several tumor cell lines suggested that loss of TSP1 expression may
contribute to tumor progression [243]. Evidence indicates that overexpression of TSP1 in
breast cancer cells, intestinal carcinoma, renal cell carcinoma, a transformed endothelial
cell line, and glioblastoma cells decreases tumor growth in animal models [244-249]. In
these contexts, it has been suggested that anti-angiogenic activity is the major mechanism
for tumor growth suppression in vivo wherein TSP1 antagonizes growth factor-stimulated
proliferation of endothelial cells and regulates vascular endothelial growth factor
bioavailability and activity [243, 250, 251]. However, high doses of exogenous TSP1 and
TSP1 peptide mimetics have demonstrated direct inhibition of breast cancer cell
proliferation in vitro [252].
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The diverse effects of TSP1 have been linked to specific epitopes in the multi-domain
molecule. As a homo-trimeric thrombospondin, TSP1 is formed by globular domains at the
N- and C-terminals. The TSP1 core contains three properdin-like type I repeats, three
epidermal growth factor (EGF)-like type II repeats and a series of calcium-binding-wiretype III repeats [253, 254]. Although not all TSP1 domains have ascribed cognate cell
surface receptors, the array of identified TSP1 receptors are extremely diverse. TSP1 has
been described to recognize integrins, proteoglycans and glycolipids among others [255258]. TSP1 directly engages CD36 and CD47 on endothelial cells to promote apoptosis
and functions related to angiogenesis [259]. TSP1 also indirectly influences the activity
and bioavailability of various mediators of angiogenesis. For example, TSP1 has the ability
to activate TGFb, a signal critical for the stability of microvasculature [260]. Recent studies
have added EGFR to the numerous signaling partners of TSP1. Although TSP1 does not
directly bind to EGFR, the EGF-like type II repeats of TSP1 promote EGFR tyrosine
phosphorylation and downstream signaling by an indirect mechanism involving matrix
metalloproteinases [261].

Tissue inhibitor of metalloproteinase-2 (TIMP2)
TIMP2, a member of the tissue inhibitor of metalloproteinase family, regulates the
proteolytic activity of matrix metalloproteinases (MMPs) [262]. Consequently, TIMP2
affects extracellular matrix (ECM) turnover, tissue remodeling and cellular behavior [262].
Independent of MMP inhibition, TIMP2 also influences cell growth, angiogenesis and
apoptosis in a context-dependent manner [262, 263]. TIMP2 induces G1 growth arrest in
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endothelial cells through de novo synthesis of the cyclin dependent kinase inhibitor p27,
resulting in inhibition of cyclin dependent kinase 2 (CDK2) and CDK4 [264, 265]. TIMP2
also promotes cell cycle arrest of post-mitotic neurons through increased production of
cyclin dependent kinase inhibitor, p21 and decreased expression of cyclins B and D [266].
Evidence has shown that exogenous TIMP2 enhances stabilization and activation of death
receptors such as TNF and Fas in metastatic colorectal cancer [267-270]. TIMP2
overexpression also exerts direct cytotoxic effects in hepatocellular carcinoma and
osteosarcoma models [271-273] wherein the pro-apoptotic effect was associated with
decreased expression of Bcl-2 and elevated levels of Bax, cleaved caspase-3 and cleaved
caspase-9 [271].

Cell surface binding of TIMP2 to distinct sites on MMPs generally regulates ECM
degradation [274-276]. The interaction of TIMP2 to MMPs is enhanced by integrins,
specifically avb3 and a3b1 [277], which also modulate phosphatase activity and related
interactions with tyrosine kinase receptors such as FGFR1, IGF-R1, VEGFR2 and EGFR
[278-281]. In these contexts, TIMP2 indirectly suppresses growth-factor mediated
mitogenic signaling by short-circuiting tyrosine kinase receptor activation [278-281].

1.6. Specific Aims
This study aims to elucidate molecular mechanism(s) underlying RENCA macrobeadmediated growth regulation of target tumor cells. Specifically, this work evaluates distinct
RENCA macrobead-secreted proteins, the contribution of EGFR signaling as well as the
requirement of MEF2 in mediating the inhibitory response of RENCA macrobeads.
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Mechanistic insight may help stratify future clinical trials to focus on patients more likely
to respond to RENCA macrobead therapy. Identification of relevant tumor-inhibitory
proteins may also allow for the development of additional assays to quantitatively evaluate
the functionality and efficacy of RENCA macrobeads prior to therapy. In the long-term,
information about the mode of action may reveal methods to potentiate the action of
RENCA macrobeads as well as expose novel vulnerabilities in tumor cells.

Our central hypothesis is that RENCA macrobeads release proteins that interact with the
cell-surface receptor EGFR and ultimately change MEF2 expression in order to restrict the
growth of external tumor cells (Figure 2).

In Aim 1, we test the hypothesis that RENCA macrobeads promote growth arrest through
regulation of MEF2 expression. 1.1) Assess whether RENCA macrobead exposure alters
MEF2 transcript levels in target tumor cells. 1.2) Determine if MEF2 expression in target
cells is required for RENCA macrobead-mediated growth inhibition, and 1.3) whether the
depletion of MEF2 isoforms in target tumor cells alters cell-cycle distribution in the
presence of RENCA macrobeads.

In Aim 2, we test the hypothesis that signaling through EGFR correlates with RENCA
macrobead-induced growth arrest and inhibition. 2.1) Assess the effect of RENCA
macrobead conditioned media on EGFR abundance and activity in target tumor cells. 2.2)
Determine whether RENCA macrobead-induced MEF2 activity is associated with EGFR
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Figure 2: Proposed model of RENCA macrobead-mediated inhibition. This thesis
tests the central hypothesis that RENCA macrobeads release proteins that interact with
the cell-surface receptor EGFR and ultimately change MEF2 expression in order to
restrict the growth of external tumor cells. The numbering refers to the three specific
aims that were pursued in this work.
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expression. 2.3) Evaluate the relationship between RENCA macrobead-mediated EGFR
phosphorylation and growth of target tumor cells, and 2.4) assess whether RENCA
macrobead-induced S-phase accumulation is linked to cellular EGFR levels.

In Aim 3, we test the hypothesis that RTN4, TSP1 and TIMP2, identified in the RENCA
macrobead secretome, inhibit growth of target tumor cells. 3.1) Validate and quantify
levels of RTN4, TSP1 and TIMP2 in RENCA macrobead conditioned media. 3.2) Assess
EGFR status, MEF2 reporter activity and MEF2 isoform expression in the presence or
absence of identified proteins, and 3.3) determine the functional impact of individual
proteins on growth of target tumor cells.
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CHAPTER 2: MATERIALS AND METHODS
2.1. Cell lines
The RENCA tumor cell line used for these experiments is a renal cortical adenocarcinoma
that arose spontaneously in Balb/c mice, originally obtained from the National Cancer
Institute (Bethesda, MD) and now available from ATCC (American Type Culture
Collection, Manassas, VA, CRL-2947). RENCA cells were maintained in RPMI 1640
(Life Technologies, Carlsbad, CA) with 10% newborn calf serum (NCS; Life
Technologies). The human prostate carcinoma cell line, DU145, originally obtained from
ATCC (HTB-81) was cultured in RPMI 1640 supplemented with 10% fetal bovine serum
(FBS; Life Technologies). The human breast adenocarcinoma MCF7 is an adherent,
epithelial luminal cell line obtained from ATCC (HTB-22) and cultured in Minimum
Essential Medium (MEM) with Earle’s salts (Sigma-Aldrich, St. Louis, MO) supplemented
with 10% FBS, 2 mM L-glutamine (Sigma-Aldrich) and 0.01 mg/mL bovine insulin
(Sigma-Aldrich). MDA-MB-231 is a highly aggressive, basal-like, triple-negative breast
cancer cell line, also obtained from ATCC (HTB-26), and cultured in RPMI 1640
supplemented with 10% FBS and 2 mM L-glutamine. In Aim 3, for assays related to
RENCA macrobead secreted proteins, 5% serum was used for cell culture with no impact
on cell growth or viability. All cell lines were maintained in tissue culture flasks at 37 °C
in 5% CO2 + air. Cell passages were limited to no more than 20 from a frozen stock of
these cells unless otherwise indicated. Routine testing for Mycoplasma contamination has
been consistently negative (Bionique Testing Laboratories, Saranac Lake, NY).
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2.2. Generation of a gefitinib-resistant cell line
Gefitinib

(N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)

quinazolin-4-amine) was purchased from Tocris (Minneapolis, MN). The gefitinibresistant subline (DU145/GRS) was established by culturing parental DU145 cells with
incrementally increasing gefitinib concentrations from 1 μM to 3 μM over 6 months.
DU145 cells were continuously maintained in gefitinib, with treatments beginning at the
initial IC50 of the DU145 parental line [282]. Following recovery of doubling time
compared to the parental DU145 cell line, the concentration of gefitinib was increased by
0.5 μM in DU145 culture media at each incremental step until gefitinib concentration was
maximal at 3 μM. A second gefitinib-resistant subline (DU145/GRC) was generated by
continuously culturing parental DU145 cells in high-dose (3 μM) gefitinib. Assessment of
resistance to gefitinib was performed every 4 passages for the first 12 passages and every
passage thereafter. DU145/GRS and DU145/GRC exhibited a 21.4 and 6.5-fold increase,
respectively, in resistance to the growth-inhibitory effect of gefitinib as determined by
MTT assay (Appendix A: Supplementary Figure 1A). The resistant phenotype had been
stable for at least 6 passages under drug-free conditions prior to use in experiments. Since
DU145/GRS cells exhibited substantially higher resistance to gefitinib, these cells were
used in subsequent studies and were hereafter designated DU145/GR. Parental DU145
cells that did not receive treatment were passaged alongside treated cells and were used at
equivalent passage numbers.
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2.3. RENCA macrobeads
RENCA macrobeads were prepared as previously described [85, 283]. Briefly,
1.5 × 105 RENCA cells were mixed with 100 μL of 0.8% low-viscosity agarose (HSB-LV;
Lonza Copenhagen ApS, Vallensbak Strand) in MEM (Sigma-Aldrich) and expelled into
mineral oil to form the core of the macrobead. Following washing with RPMI 1640, the
core was rolled in approximately 1 mL of 4.5% agarose to apply an outer coat. RENCA
macrobeads were cultured in 90-mm Petri dishes at 10 macrobeads per 40 mL of RPMI
1640 supplemented with 10% NCS for use with RENCA cells; RPMI 1640 supplemented
with 10% FBS for assays using DU145 or DU145-derivative cells; MEM with Earle’s salts
supplemented with 10% FBS, 2 mM L-glutamine and 0.01 mg/mL bovine insulin for use
with MCF7 cells or RPMI 1640 supplemented with 10% FBS and 2 mM L-glutamine for
experiments involving MDA-MB-231 cells. As described previously, for assays related to
RENCA macrobead secreted proteins, 5% serum was used for macrobead culture without
significant impact on metabolic activity or functionality. Conditioned media was collected
after 5 days of culture with RENCA macrobeads. Medium was refreshed weekly. RENCA
macrobeads used in experiments were categorized by age as young (1-3 weeks postencapsulation) or mature (greater than 18 weeks post-encapsulation) macrobeads.

2.4. Concentration of RENCA macrobead conditioned media
RENCA macrobead conditioned media was initially concentrated by culturing 40
macrobeads in 40 mL of RPMI 1640 supplemented with 5% NCS or FBS for 7 days.
Conditioned media was further concentrated by centrifugation at 3,000 × g at 4 °C using
the Macrosep Advance CFD, 3K MWCO (Pall Corporation, Michigan, ND) to convert an
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initial volume of 40 mL to a final volume of 1 mL of concentrated conditioned media. For
immunodepletion studies, 5 mL of naïve media containing protein eluate or conditioned
media, cultured at a ratio of 4 mL media per bead, was concentrated to 0.3 mL using a
Microsep Advance CFD, 3K MWCO (Pall Corporation). Concentrated media was stored
at -80 °C until further analysis. Total protein levels in concentrated conditioned media was
determined via Pierce BCA test (Thermo Scientific, Waltham, MA).

2.5. Enzyme-linked immunosorbent assay
The concentration of RTN4, TSP1 and TIMP2 proteins in culture media was determined
using commercially available ELISAs (RayBiotech, Peachtree Corners, GA) as per the
manufacturer’s instructions. Briefly, duplicate aliquots (100 µL per well) of standard
protein and concentrated conditioned media were added to pre-coated 96-well ELISA
plates. Following a 2.5 h incubation at room temperature (RT), unbound materials were
washed away, and biotinylated detection antibody (anti-RTN4, anti-TSP1, or anti-TIMP2)
was added to each well. Plates were incubated for 1 h at RT, followed by a wash step and
incubation with HRP-conjugated streptavidin solution for 45 min at RT. After a final wash
step, color development was observed following addition of 3,3,5,5’-tetramethylbenzidine
(TMB) one-step substrate solution in the dark for 30-40 minutes at RT. The reaction was
stopped by adding 50 µL per well 0.2 M sulfuric acid (stop solution). Optical density (OD)
was measured at 450 nm using a microplate reader (BioTek Model ELx800 or Synergy 2,
Winooski,VT). Sample concentrations (ng/mL) were determined based on standard
concentration curves and normalized to total protein content (ng/mg).
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2.6. Depletion of RTN4, TSP1 or TIMP2 using Protein A magnetic beads
RTN4, TSP1 or TIMP2 were immunoprecipitated from RENCA macrobead conditioned
media with PureProteome Protein A magnetic beads (Millipore, St. Louis, MO,
LSKMAGA10) and protein specific antibodies against RTN4 (13401), TSP1 (D7E5F;
37879), TIMP2 (D18B7; 5738) (Cell Signaling Technology, Danvers, MA) or Rb IgG
isotype control antibody (Abcam, Cambridge, MA, ab37415). RENCA macrobeads were
cultured in RPMI 1640 supplemented with 5% NCS or FBS at a ratio of 4 mL media per
bead for 5 days. Twenty-four hours prior to media collection, capture antibodies for RTN4,
TSP1, TIMP2 or Rb IgG isotype control were added to RENCA macrobead culture. The
following day, media containing pre-formed antibody-antigen complexes were added to
500 µL washed Protein A magnetic beads and incubated for 30 min at RT with continuous
mixing. Following incubation, conical tubes were placed in a PureProteome magnetic stand
(Millipore) and bead-free media was transferred to a fresh conical tube. This procedure
was repeated two additional times to ensure complete removal of magnetic beads. Aliquots
of conditioned media individually depleted of RTN4, TSP1 or TIMP2 were used the same
day for cell growth or gene expression assays, reporter assays and in-cell western analysis
or concentrated as described previously and stored at -80 °C until further analysis. Beads
coupled to the antibody-antigen complex were washed 5 times with PBS containing 0.1%
Tween-20 (Sigma-Aldrich) and eluted 3 times with 450 µL 0.1 M glycine (pH 2.7)
(Teknova, Hollister, CA). Eluate was neutralized with 150 µL 1 M Tris (pH 8.5) (Teknova)
for a final volume of 1.5 mL. Each eluate containing RTN4, TSP1 or TIMP2 was combined
with RPMI 1640 supplemented with 5% NCS or FBS and aliquots were used as described
above. Immunodepletion was confirmed by ELISA.
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2.7. In-cell western analysis
RENCA (90,000/cm2), DU145 (150,000/cm2), DU145/GR (150,000/cm2), MCF7
(120,000/cm2), or MDA-MB-231 (120,000/cm2) cells were seeded in 96-well black, clearbottom tissue culture-treated microplates, allowed to attach overnight, and synchronized
using serum starvation. For time course studies, cells were incubated with indicated media
for 0, 5, 15, 30, 60 (1 h), 360 (6 h), 960 (16 h), or 1440 (24 h) minutes. In all other cases,
indicated media was added to cells for 30 min, followed by pre-fixation in 2%
paraformaldehyde (PFA; EMS, Hatfield, PA) for 10 min and fixation in 4% PFA for an
additional 20 min at RT. The cells were permeabilized with 0.1% Triton X-100 in TBS
(Sigma-Aldrich) followed by incubation in Odyssey Blocking Buffer™ (LI-COR
Biosciences, Lincoln, NE) for 90 min at RT with gentle agitation. Cells were double stained
with mouse monoclonal IgG antibody against EGFR (E-8) (SCBT, Dallas, TX) together
with rabbit monoclonal IgG antibody against phosphorylated EGFR Tyr-1068 (EP774Y)
(Millipore) diluted in blocking buffer at 4 °C overnight. In wells designated as no primary
antibody controls, blocking buffer was added during the primary antibody incubation. Cells
were washed with 0.1% Tween-20 in TBS (Sigma-Aldrich) and stained with donkey antimouse IgG IRDye™ 800CW and donkey anti-rabbit IgG IRDye™ 680RD (LI-COR
Biosciences) for 1 h at RT protected from light. CellTag™ 700 (LI-COR Biosciences) was
used for cell number normalization. Images of target molecule fluorescence were obtained
using the Odyssey Infrared Imaging System (LI-COR Biosciences). Integrated intensities
of fluorescence in each well were quantified following subtraction of the average IR signal
from wells designated as no primary antibody controls.
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2.8. Cignal MEF2 reporter assay
For the Cignal MEF2 reporter assay (Qiagen, Valencia, CA), RENCA (10,000), DU145
(40,000), DU145/GR (40,000), MCF7 (25,000), or MDA-MB-231 (25,000) cells were
reverse transfected with MEF2 transcription factor-responsive luciferase reporters or
control constructs using Lipofectamine 2000 or 3000 (Life Technologies). Transiently
transfected cells were incubated with indicated media for 24h. Regulation of the MEF2
reporter was measured using the dual-luciferase reporter assay (Promega, Madison, WI)
on a Synergy 2 microplate reader (Bio-Tek). Luminescence values for the MEF2 reporter
signal (firefly luciferase, FL) and the internal control signal (Renilla luciferase, RL) were
expressed as ratios (FL/RL) to correct for variations in transfection efficiency and cell
number. Fold change in relative luciferase units (RLUs) was calculated based on
normalized luciferase activity.

2.9. RNA isolation and qRT-PCR
Total RNA was isolated from RENCA, DU145, DU145/GR, MCF7 and MDA-MB-231
cells cultured under the indicated conditions. RNA was extracted using a RNeasy mini kit
followed by genomic DNA elimination with RNase-Free DNase (Qiagen) according to
manufacturer’s recommendations. RNA concentration and quality were determined using
the Agilent 2100 RNA Bioanalyzer with the Agilent 6000 Nano Kit (Agilent Technologies,
Santa Clara, CA). To confirm RNA quality, electropherograms were evaluated where
purified RNA had an RNA Integrity Number (RIN) between 9.2 and 10. For quantitative
real-time PCR (qRT-PCR), RNA (500 ng) was reverse transcribed using the RT2 First
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Strand Kit (Qiagen). Synthesized cDNA (20 ng) was combined with 2X TaqMan® Gene
Expression Master Mix, 250 nM 6- FAM™ dye labeled TaqMan® MGB probe, and
900 nM each of forward and reverse unlabeled primers for MEF2a/A, MEF2b/B, MEF2c/C,
MEF2d/D, and the housekeeping genes, Gapdh/GAPDH and Tbp/TBP (IDT, Coralville,
IA). The primer and probe sequences used in this study are included in Appendix A:
Supplementary Tables 1A and 1B for samples of mouse and human origin respectively.
Each reaction was initially incubated at 50 °C for 2 min and 95 °C for 10 min followed by
40 cycles of denaturation at 95 °C for 15 s, annealing and extension at 60 °C for 1 min. Real
time and endpoint fluorescence data was collected with an Eppendorf Mastercycler ep
realplex 4 s (Eppendorf, Hamburg, Germany). Analysis was performed using the
comparative ΔΔCt method [284].

2.10. Cell proliferation assays
Cell proliferation of RENCA, DU145, DU145/GR, MCF7 and MDA-MB-231 cells
cultured under the indicated conditions were measured by trypan blue exclusion assay or
as previously described [85, 285]. RENCA (1,560/cm2), DU145 (3,125/cm2), DU145/GR
(3,125/cm2), MCF7 (7,810/cm2), or MDA-MB-231 (7,810/cm2) cells were seeded in 6well plates, allowed to attach overnight, and cultured with or without RENCA macrobeads
suspended in cell culture inserts (BD Biosciences, Franklin Lakes, NJ). Alternatively, cells
were seeded in 12-well plates at the same densities with conditioned media depleted of
RTN4, TSP1, or TIMP2 or fresh media containing RTN4, TSP1, or TIMP2 eluates and
related controls. Following a 5-day incubation period, cells were harvested by TrypLE™
(Gibco, Carlsbad, CA) dissociation, stained with 0.2% trypan blue solution (Sigma-
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Aldrich) and counted with a hemocytometer. In an alternate technique, cells were
methanol-fixed and stained with 0.33% (w/v) neutral red (Sigma-Aldrich). The stain was
extracted in 1.25% (w/v) sodium dodecyl sulfate (Life Technologies) and absorbance read
at 540 nm with 630 nm as the reference wavelength.

2.11. Flow cytometry analysis
To evaluate cell cycle distribution, cells were harvested by TrypLE™ (Gibco, Carlsbad,
CA) dissociation, washed in cold PBS, fixed in ice-cold 66% ethanol and incubated at 4
°C for 24 h. Fixed cells were equilibrated to RT, washed in PBS and resuspended in 400
µL PBS containing 20 µg propidium iodide and 220U RNaseA (Abcam). Cells were run,
gated and analyzed using an Accuri C6 flow cytometer (BD Biosciences). Histograms were
generated using the FCS express 4 software (De Novo Software, Glendale, CA).

2.12. Gene silencing of MEF2 isoforms
Accell SMARTpool™ siRNA constructs for knockdown of MEF2a/A, MEF2b, MEF2C or
MEF2d/D, and Accell non-targeting control siRNA were purchased from Dharmacon
(Lafayette, CO). RENCA (2,000/cm2) or DU145 (4,000/cm2) cells were seeded in 12-well
plates, allowed to attach overnight, and incubated with 1 μM siRNA in Accell delivery
media for 72 h. Media and siRNA were replenished for an additional 72-h period to
maximize gene knockdown. Knockdown was confirmed by qRT-PCR.
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2.13. Statistical analysis
Independent-sample two-tailed t tests for equal variance were performed to test for
significant differences between experimental groups and controls. Differences were
considered statistically significant at p < 0.05. All data was generated from a minimum of
three independent experiments and expressed as mean ± SD.

38

CHAPTER 3: RESULTS
3.1. Mature RENCA macrobeads modulate MEF2 transcript levels.
Since differential regulation of MEF2 isoforms during the cell cycle impacts proliferation
and survival decisions [144, 145, 147, 148, 150, 151], we sought to determine whether
factors released by RENCA macrobeads alter the expression of MEF2 in target tumor cells.
Using qRT-PCR, we measured MEF2 isoform transcript levels in RENCA and DU145
cells cultured in naïve media or together with young or mature RENCA macrobeads.
RENCA cells were used because the growth inhibitory capacity of RENCA macrobeads
throughout development is routinely assessed using these cells as targets. Moreover, early
mechanistic studies were performed in RENCA cells, making this cell line an ideal
candidate to evaluate MEF2 involvement in RENCA macrobead-mediated growth
inhibition. RENCA macrobeads have also been investigated in clinical trials as a treatment
for prostate malignancies [87]. Therefore, the DU145 cell line was included in these
experiments as a model of human prostate cancer. Since our previous studies have shown
that RENCA macrobeads inhibit tumor cell proliferation with neither species nor tumortype specificity, studies in both the murine RENCA and human DU145 cells will help
determine whether RENCA macrobead regulation of the transcription factor MEF2 is
conserved amongst species.

In RENCA cells, MEF2a expression was comparable between naïve media and different
ages of RENCA macrobeads (Figure 3A). However, following exposure to mature but not
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Figure 3: Mature RENCA macrobeads modulate MEF2 transcript levels. MEF2
isoform transcript levels were analyzed using Taqman based qRT-PCR in (A) RENCA,
and (B) DU145 cells following culture in naïve media, or co-culture with young or
mature RENCA macrobeads (RMB) for 5 days. *p-value < 0.05 relative to naïve media.
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young RENCA macrobeads, MEF2b expression was reduced by 3.90-fold while MEF2d
transcript levels significantly increased (6.30-fold) (Figure 3A). MEF2c transcripts were
not detected in RENCA cells. In DU145 cells, MEF2A expression was also similar
following culture in naïve media or different ages of RENCA macrobeads (Figure 3B).
MEF2C transcript levels were significantly reduced (1.44-fold) in the presence of mature
RENCA macrobeads but unaffected by co-culture with young RENCA macrobeads.
Additionally, MEF2D expression was decreased by 1.13-fold with young RENCA
macrobead exposure but elevated (2.72-fold) following co-culture with mature RENCA
macrobeads (Figure 3B). Expression of the MEF2B isoform was not observed in DU145
cells. These results indicate that mature RENCA macrobeads, with the capacity to inhibit
tumor growth, modulate the expression of multiple MEF2 isoforms.

3.2. MEF2D is required for RENCA macrobead-mediated growth inhibition.
RENCA macrobead regulation of MEF2 expression suggests that depletion of these
isoforms might alter RENCA macrobead-mediated growth inhibition. We investigated this
idea by transfecting tumor cell lines with MEF2 isoform-specific siRNA followed by
exposure to naïve media or RENCA macrobeads using a co-culture insert system. As
MEF2c and MEF2B were undetectable in RENCA and DU145 cells respectively, further
analysis was restricted to expressed MEF2 isoforms. In addition, we included a pooled
MEF2 siRNA condition, simultaneously depleting all expressed MEF2 isoforms in each
cell line (MEF2a, b, d siRNA for RENCA and MEF2A, C, D siRNA for DU145), to
examine the role of redundant gene family members in RENCA macrobead-induced
inhibition.
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Quantitative RT-PCR analysis of MEF2 expression confirmed knockdown efficiency to be
greater than 80% and specific to the targeted isoform, at the beginning and at the end of
the growth inhibition assay (day 0 and day 5, respectively) in RENCA (Appendix B:
Supplementary Figure 2) and DU145 (Appendix B: Supplementary Figure 3) cell lines.
Furthermore, there was no compensatory upregulation of MEF2 transcripts in response to
acute depletion of individual MEF2 isoforms.

In naïve media or following co-culture with young RENCA macrobeads, the knockdown
of MEF2a or MEF2d did not influence cell growth but gene silencing of MEF2b
significantly reduced survival in RENCA cells by 27.9% or 28.3% respectively. Similarly,
pooled MEF2a, MEF2b and MEF2d siRNAs significantly suppressed growth of RENCA
cells in naïve media (26.6%) or when cultured together with young RENCA macrobeads
(28.5%), likely due to MEF2b knockdown (Figure 4A).

Following co-culture with mature RENCA macrobeads, RENCA cells lacking siRNA
treatment (untreated) exhibited 43.8% growth inhibition, similar to the growth reduction
observed in RENCA cells transfected with NT siRNA (41.2%). In cells lacking MEF2a,
there was a significant decrease in inhibition when compared to NT siRNA (22.3% vs.
41.2%). Silencing of MEF2b in combination with mature RENCA macrobead exposure
also reduced inhibition as compared to NT siRNA treated cells but did not reveal a
substantial difference in the inhibitory response (5.1%) as compared to MEF2b knockdown
alone. However, MEF2d knockdown promoted survival in response to factors secreted by
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Figure 4: MEF2D is required for RENCA macrobead-mediated growth inhibition.
(A) RENCA and (B) DU145 cells were transfected with MEF2 isoform-specific siRNA
followed by exposure to naïve media, young or mature RENCA macrobeads for 5 days.
Cell proliferation was quantified by neutral red staining and confirmed using trypan
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mature RENCA macrobeads, increasing cell proliferation by 15.8% over baseline growth
of cells exposed to naïve media, corresponding to a 57.0% (NT siRNA
41.2% + MEF2d siRNA 15.8%) growth increase over cells treated with NT siRNA
together with mature RENCA macrobeads. Combined siRNA-mediated knockdown
(MEF2 pool) in RENCA cells also resulted in significantly enhanced cell survival (61.2%;
NT siRNA 41.2% + MEF2 pool 20.0%) following co-culture with mature RENCA
macrobeads (Figure 4A). These results indicate that expressed MEF2 isoforms contribute
to RENCA macrobead-mediated growth inhibition of RENCA cells.

Analogous to RENCA cells, MEF2A deficiency in DU145 cells did not impact growth in
naïve media or in the presence of young RENCA macrobeads but loss of MEF2A when
cultured together with mature RENCA macrobeads decreased inhibition relative to NT
siRNA (28.2% vs. 50.8%), suggesting that MEF2A partially contributes to the antiproliferative effect in this cell line (Figure 4B). In contrast, MEF2C knockdown increased
DU145 cell survival in naïve media or following co-culture with young RENCA
macrobeads but mature RENCA macrobeads restored inhibition of MEF2C-deficient
DU145 cells to levels similar to untreated cells, indicating that RENCA macrobeadmediated inhibition is MEF2C-dispensable. MEF2D depletion also resulted in a significant
increase in cell proliferation (63.0%; NT siRNA 50.8% + MEF2D 12.2%) following coculture with mature RENCA macrobeads while having no discernable effect on growth in
naïve media or in the presence of young RENCA macrobeads. Likewise, pooled MEF2
knockdown promoted survival in the presence of mature RENCA macrobeads, increasing
proliferation by 14.5% over cells cultured in naïve media which corresponded to a 65.3%
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(NT siRNA 50.8% + MEF2 pool siRNA 14.5%) growth increase over cells treated with
NT siRNA (Figure 4B). These data suggest that MEF2D is required for RENCA
macrobead induced growth inhibition of DU145 cells.

Overall, these results reveal that MEF2 family members, most notably MEF2d/D, have
distinct transcriptional functions in RENCA and DU145 cells in response to RENCA
macrobeads and suggest that these differences are critical for tumor growth control.

3.3. MEF2 depletion abrogates RENCA macrobead induced S-phase arrest.
MEF2 isoforms, specifically MEF2C and MEF2D, have been described to inhibit
proliferation by inducing p21 expression [148] which can lead to accumulation of cells in
S-phase [286]. Since mature RENCA macrobeads suppress proliferation of freely growing
cancer cells by inducing S-phase arrest [85] and RENCA macrobeads modulate MEF2
isoform expression, we sought to determine whether the depletion of MEF2 isoforms in
target tumor cells alters cell-cycle distribution in the presence of RENCA macrobeads.

In naïve media or following co-culture with young RENCA macrobeads, knockdown of
MEF2b or combined silencing of expressed MEF2 isoforms in RENCA cells increased Sphase accumulation with an associated decrease in the percentage of cells in G1 phase
(Figure 5). Consistent with previous observations [85], culture of RENCA cells with
mature RENCA macrobeads impaired progression through S-phase (23.7% vs. 8.0% for
cells cultured in naïve media) with a corresponding decrease in G1 (31.7% vs. 43.8%) and
G2/M phases (44.6% vs. 48.1%). A similar pattern of cell-cycle distribution was observed

45

A.

Count

Naïve Media

Young RMB Co-Culture

Mature RMB Co-Culture

2000

2000

2000

1500

1500

1500

1000

1000

1000

500

500

500

0

0

0

1500

1500

1500

1000

1000

1000

500

500

500

0

0

0

1500

1500

1500

1000

1000

1000

500

500

500

0

0

0

1500

1500

1500

1000

1000

1000

500

500

500

0

0

0

1500

1500

1500

1000

1000

1000

500

500

500

0

0

0

1500

1500

1500

1000

1000

1000

500

500

500

0

2N

0

4N

2N

G1

UT

NT
siRNA

MEF2a
siRNA

MEF2b
siRNA

MEF2d
siRNA

MEF2pool
siRNA

0

4N

S

2N

4N

G2/M

% cells in G1 phase

B.
60

60

60

50

50

50

40

^

^

40

40

*

30

30

20

20

20

10

10

10

0

Naïve Media

% cells in S phase

^

30

0

60

50

50

50

40

40

40

30

30

30

20

20

20

^

^

10

0

^

NT
siRNA

MEF2a
siRNA

*

*

MEF2b
siRNA

^
* ^

10

0

Naïve Media

^
^ *

MEF2d
siRNA

0

Young RMB
Co-Culture

Mature RMB
Co-Culture

60

60

60

50

50

50

40

40

40

30

30

30

20

20

20

10

10

10

0

0

Naïve Media

UT

Mature RMB
Co-Culture

60

^

*

^
^ ^ ^ *
*

0

Young RMB
Co-Culture

60

10

% cells in G2/M phase

^

*

*

^

MEF2pool
siRNA

^ ^

0

Young RMB
Co-Culture

Mature RMB
Co-Culture

Figure 5: MEF depletion abrogates RENCA macrobead induced S-phase arrest in
RENCA cells. (A) Cell cycle profiles with pie charts and (B) the percentage of the cell
population in each phase of the cell cycle in RENCA cells transfected with MEF2
isoform-specific siRNA followed by exposure to naïve media, young or mature RENCA
macrobeads after 5 days. p-value < 0.05 relative to NT siRNA within a culture condition
(^) or relative to naïve media with the same siRNA knockdown (*).
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for cells transfected with NT siRNA in the presence of RENCA macrobeads (G1: 32.7%;
S: 22.1%; G2/M: 45.2%).

Depletion of MEF2 isoforms abrogated RENCA macrobead-induced S-phase arrest
(Figure 5). In cells lacking MEF2a, there was a significant decrease in the percentage of
cells in S-phase (15.4% vs. 22.1%) accompanied by an increase in G1 phase (37.1% vs.
32.7%). Silencing of MEF2b also reduced S-phase accumulation (14.8%) and increased
G1 (36.7%) and G2/M (48.4%) phase populations as compared to NT siRNA treated cells
but did not reveal a significant difference in cell cycle distribution when compared to
MEF2b knockdown alone. Loss of MEF2d completely abolished S-phase accumulation to
levels comparable to naïve media, supporting a critical role for this isoform in inducing
RENCA macrobead-mediated S-phase arrest (Figure 5). Combined siRNA-mediated
knockdown in RENCA cells also resulted in significantly reduced S-phase accumulation
(9.0%) following co-culture with mature RENCA macrobeads. These results indicate that
MEF2a, MEF2b and particularly, the MEF2d isoform contribute to RENCA macrobeadmediated S-phase accumulation of RENCA cells.

In the DU145 cell line, depletion of MEF2 isoforms did not influence cell cycle profiles
when cultured in naïve media or following co-culture with young RENCA macrobeads;
however, the presence of mature RENCA macrobeads significantly altered cell cycle phase
distribution (Figure 6). Following co-culture with mature RENCA macrobeads, untreated
DU145 cells accumulated in S-phase (24.8% vs. 14.4% for cells cultured in naïve media)
along with a significant decrease in G1 (44.1% vs. 48.0%) and G2/M phases (31.1% vs.
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Figure 6: MEF depletion abrogates RENCA macrobead induced S-phase arrest in
DU145 cells. (A) Cell cycle profiles with pie charts and (B) the percentage of the cell
population in each phase of the cell cycle in DU145 cells transfected with MEF2
isoform-specific siRNA followed by exposure to naïve media, young or mature RENCA
macrobeads after 5 days. p-value < 0.05 relative to NT siRNA within a culture condition
(^) or relative to naïve media with the same siRNA knockdown (*).
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37.6%), similar to the cell cycle distribution profiles of DU145 cells transfected with NT
siRNA (G1: 45.2%; S: 25.0%; G2/M: 29.8%).

Loss of MEF2A decreased S-phase arrest (18.8%) with a moderate increase in G2/M phase
(35.4%) (Figure 6). MEF2C knockdown also reduced S-phase accumulation (14.7%) in
comparison to NT siRNA but surprisingly, a large proportion of MEF2C depleted DU145
cells accumulated in G2/M phase (51.3%) (Figure 6), suggesting an alternative mechanism
for RENCA macrobead-induced growth arrest in the absence of MEF2C for this cell line.
Analogous to RENCA cells, silencing of MEF2D or combined knockdown of MEF2
isoforms in DU145 cells abrogated S-phase accumulation, suggesting a conserved role for
MEF2D in mediating RENCA macrobead-induced S-phase arrest (Figure 6). Overall, these
results demonstrate a critical role for MEF2 isoforms in RENCA macrobead-induced cellcycle regulation of DU145 cells in vitro, similar to the role of MEF2 in RENCA cells as
shown above.

3.4. Mature RENCA macrobead-induced upregulation of EGFR activity correlates
with levels of functional EGFR expression.
Regulation of transcriptional programs that control cell fate can occur in response to
extracellular signals acting through cell surface receptors. Our preliminary studies
indicated that mature RENCA macrobeads increase the levels of total and phosphorylated
EGFR in RENCA cells. Overexpression of EGF receptor and activation of EGFR-tyrosine
kinase induces growth inhibition, cell cycle arrest and apoptosis in specific contexts [165,
166, 169, 170, 175, 287], suggesting a possible signaling link that translates RENCA
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macrobead-released signals into an inhibitory response. Therefore, we evaluated the
association between EGFR expression or tyrosine kinase responsiveness and RENCA
macrobead-mediated growth suppression using a panel of four cell lines: DU145,
DU145/GR, MDA-MB-231 and MCF7. The human prostate cancer cell line DU145
harbors wild-type EGFR gene amplification with an estimated 2.4 – 4×105 EGFRs per cell
[288-290]. DU145/GR cells, as described in Chapter 2, are a gefitinib-resistant subline
generated through chronic adaptation with the tyrosine kinase inhibitor, gefitinib. These
cells exhibit weak tyrosine kinase activity in the presence of EGF as compared to the
parental DU145 cell line (Appendix A: Supplementary Figure 1). MDA-MB-231 is an
epithelial-derived basal breast cancer cell line reported to express EGFR at high levels
(~7×105 EGFRs/cell) [291] while MCF7, an epithelial-derived luminal A breast cancer cell
line has substantially lower levels of EGFR expression (~8×102 EGFRs/cell) [291, 292].

To better understand whether the relative levels of EGF receptor correlate with the ability
of RENCA macrobeads to inhibit cell growth, we used in-cell western analysis to assess
the relative expression and activation (pY1068) of EGFR in response to RENCA
macrobead-released signals in each cell line. Whereas young RENCA macrobead
conditioned media had a negligible effect on EGFR abundance and activity as compared
to cells cultured in naïve media, mature RENCA macrobead conditioned media
significantly increased EGFR expression (3.9-fold) and activation (2.3-fold) in DU145
cells (Figure 7A). In contrast, DU145/GR cells, demonstrated a moderate upregulation of
total (1.8-fold) and phosphorylated EGFR (1.5-fold) (Figure 7B) despite having similar
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Figure 7: Mature RENCA macrobead-induced upregulation of EGFR activity
correlates with levels of functional EGFR expression. The relative expression of
EGFR and pY1068 was detected via in-cell western analysis 30-minutes following
exposure to naïve media or conditioned media from young or mature RENCA
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basal receptor expression and pY1068 levels as the parental DU145 cell line (Appendix A:
Supplementary Figure 1B). MDA-MB-231 cells also exhibited elevated EGFR (3.5-fold)
and pY1068 (2.2-fold) (Figure 7C); however, no changes in total EGFR or pY1068 levels
were observed in MCF7 cells (Figure 7D). These data demonstrate that mature RENCA
macrobead-induced upregulation of EGFR expression and activity correlates with levels of
functional EGFR.

3.5. Mature RENCA macrobeads sustain activated EGFR signaling in cells with
high levels of functional EGF receptor.
Experiments in multiple cell types have shown that the specificity of cellular responses
depends on EGFR signal duration (e.g., whether EGFR activation is transient or sustained)
[287, 293, 294]. Therefore, signaling through the same pathway may result in entirely
different outputs depending on the amplitude and persistence of receptor activation. To
explore the temporal regulation of EGFR in response to RENCA macrobeads, EGFR
expression and phosphorylation was assessed in cell lines exposed to naïve or conditioned
media from varied ages of RENCA macrobeads over a 24-hour period. Naïve media or
young RENCA macrobead-treated DU145 cells demonstrated an early, transient increase
in EGFR phosphorylation accompanied by a modest upregulation of EGFR expression. In
contrast, exposure of DU145 cells to conditioned media from mature RENCA macrobeads
prompted a rapid and sustained increase in total and activated EGFR that remained
relatively stable for 24 hours following initial stimulation (Figure 8A). A comparable
pattern of EGFR expression and activation kinetics was observed in the MDA-MB-231
cell line (Figure 8C). Although DU145/GR cells in naïve or young RENCA macrobead
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Figure 8: Mature RENCA macrobeads sustain activated EGFR signaling in cells
with high levels of functional EGF receptor. Time course of EGFR (top panel) and
pY1068 (bottom panel) expression in (A) DU145, (B) DU145/GR, (C) MDA-MB-231,
and (D) MCF7 cells following exposure to naïve media or conditioned media from
young or mature RENCA macrobeads. Each datapoint represents protein expression
relative to time = 0.
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conditioned media exhibited similar activation kinetics to the parental DU145 cell line,
mature RENCA macrobead treatment induced only moderately elevated total and pY1068
levels, returning to baseline within 1-6 hours following initial stimulation (Figure 8B).
Comparatively, MCF7 cells exhibited a complete lack of response in activity throughout
the time course regardless of the type of media exposure (Figure 8D). This demonstrates
that mature RENCA macrobead-released signals extend EGFR engagement in cells
overexpressing functional EGFR.

3.6. Association between levels of functional EGFR and RENCA macrobeadinduced MEF2 activity and expression.
Downstream effectors of EGFR signaling, such as BMK1, ERK5 and p38, influence MEF2
transcriptional activity [295, 296]. Therefore, we sought to examine the extent to which
RENCA macrobead-induced EGFR signaling is associated with MEF2 reporter activity. In
all cell lines tested, mature but not young RENCA macrobeads increased MEF2 reporter
activity as compared to cells cultured in naïve media (DU145: 35.1-fold; DU145/GR; 10.4fold; MDA-MB-231: 15.5-fold; MCF7: 3.4-fold) (Figure 9A-D). However, mature
RENCA macrobead-induced MEF2 activity was significantly greater in cell lines with
higher expression of functional EGFR.

Components of MEF2 transcriptional regulation are also dependent on ERK and Ras
signaling, likely downstream of EGFR [295, 296]. Since mature RENCA macrobeads
modulate MEF2 transcript levels, we determined whether signaling through EGFR
correlated with MEF2 isoform expression in the presence of RENCA macrobeads.
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Figure 9: Association between levels of functional EGFR and RENCA macrobeadinduced MEF2 activity. (A) DU145, (B) DU145/GR, (C) MDA-MB-231, and (D)
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Following exposure to mature RENCA macrobeads, MEF2C transcript levels were
reduced in cells overexpressing EGFR, specifically 1.44-fold in DU145 cells (Figure 10A)
and 1.18-fold in MDA-MB-231 cells (Figure 10C) but MEF2C mRNA was comparable to
naïve media in DU145/GR (Figure 10B) and MCF7 cells (Figure 10D). Additionally,
MEF2D expression was significantly increased in all cell lines (DU145: 2.72-fold;
DU145/GR; 1.34-fold; MDA-MB-231: 6.49-fold; MCF7: 1.27-fold) in response to mature
RENCA macrobeads (Figure 10). However, it is noted that RENCA macrobead-induced
mRNA levels of MEF2D were greater in cells with EGFR overexpression. Overall, these
data demonstrate that the level of MEF2 activity and isoform-specific expression induced
by mature RENCA macrobead exposure is associated with the level of EGFR expression
in the tested cell lines.

3.7. EGFR overexpression correlates with sensitivity to growth inhibition by mature
RENCA macrobeads.
To investigate whether the extent of RENCA macrobead-mediated growth inhibition
depended on EGFR expression levels or responsiveness, cells cultured in naïve media or
together with RENCA macrobeads were stained with neutral red and percent survival was
calculated based on naïve cultures. Results were confirmed using the trypan blue exclusion
assay. Young RENCA macrobeads did not significantly impact cell survival in any of the
tested cell lines as compared to cells cultured in naïve media. However, mature RENCA
macrobeads inhibited proliferation of DU145 (Figure 11A), DU145/GR (Figure 11B),
MDA-MB-231 (Figure 11C) and MCF7 (Figure 11D) cells by 40.8% (DU145), 16.0%
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Figure 11: EGFR overexpression correlates with sensitivity to growth inhibition
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58

(DU145/GR), 55.3% (MDA-MB-231) and 16.4% (MCF7), as compared to naïve media.
These results demonstrate that sensitivity to growth inhibition induced by mature RENCA
macrobeads is correlated with the level of functional EGFR expression.

3.8. RENCA macrobead-induced S-phase accumulation correlates with levels of
functional EGFR expression.
As S-phase accumulation is a prominent feature of RENCA macrobead-mediated
suppression of freely growing cancer cells [85] and regulation of EGFR modulates cell
cycle progression [297], we sought to examine whether EGFR status is associated with
RENCA macrobead-induced cell cycle inhibition. Co-culturing DU145 cells with mature
RENCA macrobeads significantly increased S-phase accumulation (24.8% vs. 14.4%),
thereby reducing the proportion of cells in G1 (44.1% vs. 48.0%) and G2/M phases (31.1%
vs. 37.6%), compared to cells cultured in naïve media (Figure 12A). Contrastingly,
comparable numbers of DU145/GR cells were identified in S-phase regardless of culture
medium (Figure 12B), supporting a central role for functionally active EGFR in
transducing RENCA macrobead-released signals into intracellular growth inhibitory
responses that promote S-phase arrest. Interestingly, in DU145/GR cells, a significant
increase in the proportion of cells that accumulated in G2/M phase and a concomitant
decrease in G1 phase was observed in the presence of mature but not young RENCA
macrobeads (Figure 12B), suggesting a secondary mechanism by which RENCA
macrobeads could inhibit growth in the absence of functionally active EGFR. Furthermore,
this supports the notion that RENCA macrobeads impede multiple processes essential for
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Figure 12: RENCA macrobead-induced S-phase accumulation correlates with
levels of functional EGFR expression. Cell cycle profiles with pie charts (top) and
graphs (bottom) showing the percentage of the cell population in each phase of the cell
cycle in (A) DU145, (B) DU145/GR, (C) MDA-MB-231, and (D) MCF7 cells following
exposure to naïve media, young or mature RENCA macrobeads for 5 days. *p-value <
0.05 relative to naïve cultures.

tumor cell proliferation. Analogous to DU145 cells, significantly more MDA-MB-231
cells accumulated in S-phase when cultured with mature RENCA macrobeads (20.5%)
with an associated decrease in G1 phase as compared to naïve media (14.1%) or co-culture
with young RENCA macrobeads (14.0%) (Figure 12C). MCF7 cells cultured in naïve
media or together with young RENCA macrobeads aggregated in G1 phase and had a
relatively even distribution of S and G2/M populations. However, exposure to mature
RENCA macrobeads caused a cell cycle shift, with significantly fewer cells accumulating
in S-phase (15.6% vs. 24.9%) while a large proportion collected in the G2/M phase (50.0%
vs. 19.9%) (Figure 12D). These results demonstrate that signaling through EGFR correlates
with RENCA macrobead-induced S-phase cell accumulation.

3.9. RTN4, TSP1 and TIMP2 are present in the RENCA macrobead secretome.
Data presented thus far supports the idea that EGFR overexpression and activation
correlates with sensitivity to RENCA macrobead-induced inhibition. EGF-like ligands,
such as RTN4, TSP1 and TIMP2, identified by mass spectrometry in conditioned media of
RENCA macrobeads at different stages of development, have reported tumor suppressive
functions [218, 223, 224, 243, 244, 246, 249, 252, 266, 272, 273] and consequently, may
participate in RENCA macrobead-mediated growth inhibition of target tumor cells. Thus,
we sought to confirm the presence of these proteins in conditioned media collected from
RENCA macrobeads followed by characterizing their roles in growth inhibition.

Using an ELISA, we quantified levels of RTN4, TSP1 and TIMP2 in RENCA macrobead
conditioned media. Each target protein was detected (~540 pg – 15 ng/mg total protein) in
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5% NCS
5% FBS

RTN4 (ng/mg)

TSP1 (ng/mg)

TIMP2 (ng/mg)

Naïve Media

ND

ND

ND

Young RMB Media

ND

ND

0.031 ± 0.011

Mature RMB Media

0.546 ± 0.073

11.644 ± 1.676

1.533 ± 0.259

Naïve Media

ND

ND

ND

Young RMB Media

ND

ND

0.058 ± 0.008

Mature RMB Media

0.611 ± 0.089

14.381 ± 2.174

1.629 ± 0.317

Table 1: RTN4, TSP1 and TIMP2 levels in naïve and RENCA macrobead
conditioned media. Concentrated naïve and conditioned media from young or mature
RENCA macrobeads was analyzed by ELISA for RTN4, TSP1 and TIMP2. NCS and
FBS cultures were concentrated and quantified separately to establish baseline
measurements for comparison with future tests involving RENCA and DU145 cells
respectively. ND, not detected in tested media with the following detection limits:
RTN4 £ 0.012 ng/mg; TSP1 £ 0.165 ng/mg; TIMP2 £ 0.002 ng/mg. Values represent
quantity (ng) of detected protein relative to total protein (mg).
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concentrated conditioned media from mature RENCA macrobeads but none were
identified in concentrated naïve cultures. In young RENCA macrobead concentrated
conditioned media, RTN4 and TSP1, if present, were below the detection limit of the assay
and TIMP2, although detected, was present at a lower abundance (~25-50-fold) as
compared to concentrated conditioned media from mature RENCA macrobeads (Table 1).

3.10. RTN4, TSP1 and TIMP2 partially contribute to RENCA macrobead-induced
EGFR activation.
To confirm whether RTN4, TSP1 and TIMP2, present at expressed levels in RENCA
macrobead conditioned media, influence EGFR status in RENCA, DU145, and DU145/GR
cells, we assessed the relative expression of EGFR and levels of pY1068 using (1) media
individually immunodepleted of each of the detected proteins or (2) naïve media to which
protein eluate, recovered from the immunodepletion process, were added.

RTN4, TSP1 and TIMP2 were not detected following precipitation from mature RENCA
macrobead conditioned media, suggesting effective depletion using Protein A magnetic
beads. Furthermore, similar levels of each protein were observed in the eluate fraction as
compared to mock depletion (Rb IgG), confirming successful recovery of depleted proteins
(Appendix B: Supplementary Table 2). TIMP2 was not detected in the eluate recovered
from immunodepleted young RENCA macrobead conditioned media (data not shown)
likely because levels were below the detection limit of the ELISA. As such, further analysis
was restricted to proteins depleted from mature RENCA macrobead conditioned media.

63

RTN4-depleted mature RENCA macrobead conditioned media significantly decreased
total and phosphorylated EGFR levels in both RENCA and DU145 cells but had no effect
in DU145/GR cells (Figure 13A-C). However, addition of RTN4 eluate to naïve media
enhanced EGFR activation in RENCA and DU145 cells with no impact on total EGFR
levels (Figure 13D-E). No changes in EGFR status were observed in DU145/GR cells upon
treatment with RTN4 eluate (Figure 13F). Similar to RTN4, depletion of TSP1 reduced
total and phosphorylated EGFR levels in both RENCA and DU145 cells but not
DU145/GR cells (Figure 14A-C). In comparison, TSP1 eluate increased total and
phosphorylated levels in RENCA (Figure 14D) but only altered pY1068 in DU145 cells
(Figure 14E) with a lack of effect in DU145/GR cells (Figure 14F). TIMP2 depletion
reduced total EGFR in RENCA and DU145 cells with a negligible impact on pY1068
levels (Figure 15A-B). Supplementation of naïve media with TIMP2 eluate also increased
total EGFR expression in RENCA and DU145 cells (Figure 15D-E). TIMP2, whether
depleted from mature RENCA macrobead conditioned media or added to naive media, had
no effect on EGFR status in the DU145/GR cell line (Figure 15C, F). These data suggest
that while each protein partially contributes to the observed increase in mature RENCA
macrobead-induced EGFR expression, RTN4 and TSP1 are required for maximal EGFR
phosphorylation. These studies also demonstrate that individual macrobead-released
proteins independently influence EGFR status. However, the fractional contribution of
each protein to the observed increase in mature RENCA macrobead-induced EGFR
expression and activation suggests that these proteins act in concert with additional proteins
to elicit the maximal response.
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Figure 13: Mature RENCA macrobead-released RTN4 partially contributes to
EGFR activation. The relative expression of EGFR and pY1068 was detected via incell western analysis 30-minutes following exposure to RTN4-depleted mature RENCA
macrobead conditioned media (A-C) or naïve media to which RTN4, eluted from
immunodepleted media, was added (D-F) in (A, D) RENCA, (B, E) DU145, and (C, F)
DU145/GR cells. CellTag 700 stain was used for normalization to cell number. X-axis
includes (A-C) naïve media (Naïve), Rb IgG depleted (Mock), or protein-specific
depletion (-RTN4) from mature RENCA macrobead conditioned media and (D-F)
mature RENCA macrobead conditioned media (Mature), Rb IgG added (Naïve), or
protein-specific addition (+RTN4) to naïve media. Y-axis represents the fold change in
protein levels relative to Rb IgG (Mock) depleted mature RENCA macrobead
conditioned media (A-C) or Rb IgG added to naïve media (Naïve) (D-F). *p-value <
0.05 relative to Mock in A-C or Naïve in D-F.
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Figure 14: Mature RENCA macrobead-released TSP1 partially contributes to
EGFR activation. The relative expression of EGFR and pY1068 was detected via incell western analysis 30-minutes following exposure to TSP1-depleted mature RENCA
macrobead conditioned media (A-C) or naïve media to which RTN4, eluted from
immunodepleted media, was added (D-F) in (A, D) RENCA, (B, E) DU145, and (C, F)
DU145/GR cells. CellTag 700 stain was used for normalization to cell number. X-axis
includes (A-C) naïve media (Naïve), Rb IgG depleted (Mock), or protein-specific
depletion (-TSP1) from mature RENCA macrobead conditioned media and (D-F)
mature RENCA macrobead conditioned media (Mature), Rb IgG added (Naïve), or
protein-specific addition (+TSP1) to naïve media. Y-axis represents the fold change in
protein levels relative to Rb IgG (Mock) depleted mature RENCA macrobead
conditioned media (A-C) or Rb IgG added to naïve media (Naïve) (D-F). *p-value <
0.05 relative to Mock in A-C or Naïve in D-F.
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Figure 15: Mature RENCA macrobead-released TIMP2 partially contributes to
EGFR activation. The relative expression of EGFR and pY1068 was detected via incell western analysis 30-minutes following exposure to TIMP2-depleted mature
RENCA macrobead conditioned media (A-C) or naïve media to which RTN4, eluted
from immunodepleted media, was added (D-F) in (A, D) RENCA, (B, E) DU145, and
(C, F) DU145/GR cells. CellTag 700 stain was used for normalization to cell number.
X-axis includes (A-C) naïve media (Naïve), Rb IgG depleted (Mock), or proteinspecific depletion (-TIMP2) from mature RENCA macrobead conditioned media and
(D-F) mature RENCA macrobead conditioned media (Mature), Rb IgG added (Naïve),
or protein-specific addition (+TIMP2) to naïve media. Y-axis represents the fold change
in protein levels relative to Rb IgG (Mock) depleted mature RENCA macrobead
conditioned media (A-C) or Rb IgG added to naïve media (Naïve) (D-F). *p-value <
0.05 relative to Mock in A-C or Naïve in D-F.
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3.11.

RTN4, TSP1 and TIMP2 differentially regulate MEF2 activity and expression.

Next, we determined the extent to which RENCA macrobead-secreted RTN4, TSP1 or
TIMP2 contributes to MEF2 activity. Depletion of RTN4 from conditioned media of
mature macrobeads resulted in decreased MEF2 activity in both RENCA and DU145 cells
(1.89-fold and 1.48-fold, respectively), but not DU145/GR cells (Figure 16A-C). Addition
of the RTN4 eluate significantly increased MEF2 activity in RENCA and DU145 cells
(1.97-fold and 3.96-fold, respectively) with no impact on DU145/GR cells (Figure 16DF). TSP1 depletion also reduced MEF2 activity in DU145 cells (1.94-fold) but had no effect
on RENCA or DU145/GR cells (Figure 17A-C). Introduction of TSP1 to naïve media
increased activity in the DU145 cell line (4.94-fold) with no impact on RENCA or
DU145/GR cells (Figure 17D-F). Comparable to RTN4, TIMP2-depletion decreased
MEF2 activity in both RENCA and DU145 cells (1.50-fold and 1.51-fold, respectively)
(Figure 18A-B) while addition of TIMP2 significantly increased MEF2 activity (3.45-fold
and 6.38-fold, respectively) (Figure 18D-E). Altering TIMP2 levels in media (i.e. depletion
from mature RENCA macrobead conditioned media or addition to naïve media) had no
effect on MEF2 activity in the DU145/GR cell line (Figure 18C, F). These studies
demonstrate that although tumor target cell-specific differences exist, individual proteins
present in mature RENCA macrobead conditioned media can independently influence
MEF2 reporter activity.

To determine whether RTN4, TSP1 or TIMP2 from mature RENCA macrobeads modulate
MEF2 transcript levels in target tumor cells, we measured MEF2 isoform mRNA using
qRT-PCR. While mock depletion has no effect on MEF2 isoform expression in any of the
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Figure 16: Cell-specific induction of MEF2 activity by mature RENCA
macrobead- secreted RTN4. (A, D) RENCA, (B, E) DU145, and (C, F) DU145/GR
cells transiently transfected with the MEF2 reporter were exposed to (A-C) RTN4depleted mature RENCA macrobead conditioned media or (D-F) naïve media to which
RTN4, eluted from immunodepleted media, was added. Luminescence values for the
MEF2 reporter signal was measured using a dual-luciferase reporter assay and
normalized to the internal control signal, Renilla. X-axis includes (A-C) naïve media
(Naïve), Rb IgG depleted (Mock), or protein-specific depletion (-RTN4) from mature
RENCA macrobead conditioned media and (D-F) mature RENCA macrobead
conditioned media (Mature), Rb IgG added (Naïve), or protein-specific addition
(+RTN4) to naïve media. Y-axis represents the fold change in MEF2 activity relative to
Rb IgG (Mock) depleted mature RENCA macrobead conditioned media (A-C) or Rb
IgG added to naïve media (Naïve) (D-F). *p-value < 0.05 relative to Mock in A-C or
Naïve in D-F.
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Figure 17: Cell-specific induction of MEF2 activity by mature RENCA
macrobead- secreted TSP1. (A, D) RENCA, (B, E) DU145, and (C, F) DU145/GR
cells transiently transfected with the MEF2 reporter were exposed to (A-C) TSP1depleted mature RENCA macrobead conditioned media or (D-F) naïve media to which
TSP1, eluted from immunodepleted media, was added. Luminescence values for the
MEF2 reporter signal was measured using a dual-luciferase reporter assay and
normalized to the internal control signal, Renilla. X-axis includes (A-C) naïve media
(Naïve), Rb IgG depleted (Mock), or protein-specific depletion (-TSP1) from mature
RENCA macrobead conditioned media and (D-F) mature RENCA macrobead
conditioned media (Mature), Rb IgG added (Naïve), or protein-specific addition
(+TSP1) to naïve media. Y-axis represents the fold change in MEF2 activity relative to
Rb IgG (Mock) depleted mature RENCA macrobead conditioned media (A-C) or Rb
IgG added to naïve media (Naïve) (D-F). *p-value < 0.05 relative to Mock in A-C or
Naïve in D-F.
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Figure 18: Cell-specific induction of MEF2 activity by mature RENCA
macrobead- secreted TIMP2. (A, D) RENCA, (B, E) DU145, and (C, F) DU145/GR
cells transiently transfected with the MEF2 reporter were exposed to (A-C) TIMP2depleted mature RENCA macrobead conditioned media or (D-F) naïve media to which
TIMP2, eluted from immunodepleted media, was added. Luminescence values for the
MEF2 reporter signal was measured using a dual-luciferase reporter assay and
normalized to the internal control signal, Renilla. X-axis includes (A-C) naïve media
(Naïve), Rb IgG depleted (Mock), or protein-specific depletion (-TIMP2) from mature
RENCA macrobead conditioned media and (D-F) mature RENCA macrobead
conditioned media (Mature), Rb IgG added (Naïve), or protein-specific addition
(+TIMP2) to naïve media. Y-axis represents the fold change in MEF2 activity relative
to Rb IgG (Mock) depleted mature RENCA macrobead conditioned media (A-C) or Rb
IgG added to naïve media (Naïve) (D-F). *p-value < 0.05 relative to Mock in A-C or
Naïve in D-F.
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Figure 19: Mature RENCA macrobead-released RTN4 differentially regulates
MEF2 expression. MEF2 isoform transcript levels were analyzed using Taqman based
qRT-PCR in (A, D) RENCA, (B, E) DU145, and (C, F) DU145/GR cells 5 days
following exposure to (A-C) RTN4-depleted mature RENCA macrobead conditioned
media or (D-F) naïve media to which RTN4, eluted from immunodepleted media, was
added. (A-C) naïve media, Rb IgG depleted (Mock Depleted), or protein-specific
depletion (-RTN4) from mature RENCA macrobead conditioned media and (D-F)
mature RENCA macrobead conditioned media, Rb IgG added, or protein-specific
addition (+RTN4) to naïve media were included. Y-axis represents the fold change in
transcript levels relative to Mock depleted mature RENCA macrobead conditioned
media (A-C) or Rb IgG added to naïve media (D-F). *p-value < 0.05 relative to Mock
Depleted in A-C or Naïve Media + Rb IgG in D-F.
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Figure 20: Mature RENCA macrobead-released TSP1 differentially regulates
MEF2 expression. MEF2 isoform transcript levels were analyzed using Taqman based
qRT-PCR in (A, D) RENCA, (B, E) DU145, and (C, F) DU145/GR cells 5 days
following exposure to (A-C) TSP1-depleted mature RENCA macrobead conditioned
media or (D-F) naïve media to which TSP1, eluted from immunodepleted media, was
added. (A-C) naïve media, Rb IgG depleted (Mock Depleted), or protein-specific
depletion (-TSP1) from mature RENCA macrobead conditioned media and (D-F)
mature RENCA macrobead conditioned media, Rb IgG added, or protein-specific
addition (+TSP1) to naïve media were included. Y-axis represents the fold change in
transcript levels relative to Mock depleted mature RENCA macrobead conditioned
media (A-C) or Rb IgG added to naïve media (D-F). *p-value < 0.05 relative to Mock
Depleted in A-C or Naïve Media + Rb IgG in D-F.
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Figure 21: Mature RENCA macrobead-released TIMP2 differentially regulates
MEF2 expression. MEF2 isoform transcript levels were analyzed using Taqman based
qRT-PCR in (A, D) RENCA, (B, E) DU145, and (C, F) DU145/GR cells 5 days
following exposure to (A-C) TIMP2-depleted mature RENCA macrobead conditioned
media or (D-F) naïve media to which TIMP2, eluted from immunodepleted media, was
added. (A-C) naïve media, Rb IgG depleted (Mock Depleted), or protein-specific
depletion (-TIMP2) from mature RENCA macrobead conditioned media and (D-F)
mature RENCA macrobead conditioned media, Rb IgG added, or protein-specific
addition (+TIMP2) to naïve media were included. Y-axis represents the fold change in
transcript levels relative to Mock depleted mature RENCA macrobead conditioned
media (A-C) or Rb IgG added to naïve media (D-F). *p-value < 0.05 relative to Mock
Depleted in A-C or Naïve Media + Rb IgG in D-F.
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studied cell lines (data not shown), RTN4-depleted mature RENCA macrobead
conditioned media significantly decreased MEF2d expression in RENCA and DU145 cells
(Figure 19A-B). Removal of RTN4 also restored MEF2C expression in DU145 cells to
levels present in naïve media (Figure 19B) while addition of this protein to naïve media
had no effect on MEF2 isoform expression (Figure 19D-F). Depletion of TSP1 increased
MEF2b transcripts in RENCA cells and although not significant, displayed a tendency
towards decreased expression of MEF2d gene transcripts (Figure 20A). In the DU145 cell
line, removal of TSP1 protein from mature RENCA macrobead conditioned media reduced
MEF2A and MEF2D expression (Figure 20B). Similar to RTN4, addition of TSP1 to naïve
media had a negligible impact on MEF2 isoform expression in any of the assessed cell lines
(Figure 20D-F). TIMP2-depletion also reduced the MEF2d/D isoform in RENCA and
DU145 cells (Figure 21A-B). Furthermore, supplementation of naïve media with TIMP2
eluate increased MEF2d/D transcripts in RENCA and DU145 (Figure 21D-E) cells. As
observed in other contexts, depletion or addition of RTN4 (Figure 19C, F), TSP1 (Figure
20C, F) or TIMP2 (Figure 21C, F) had no effect on MEF2 isoform expression in
DU145/GR cells.

3.12. RTN4, TSP1 and TIMP2 are necessary, but not individually sufficient, to
achieve the full inhibitory capacity of RENCA macrobeads.
Finally, we investigated the functional relevance of protein depletion on growth of target
cells. Culture of cell lines in Rb IgG depleted media did not have an appreciable effect on
growth as compared to non-manipulated mature RENCA macrobead conditioned media
(data not shown). Depletion of RTN4, TSP1 or TIMP2 from mature RENCA macrobead
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conditioned media significantly increased survival of RENCA (Figure 22-24A) and DU145
cells (Figure 22-24B) relative to mock (Rb IgG) depleted media, suggesting that these
proteins partially contribute to mature RENCA macrobead-mediated growth inhibition.
However, individual depletion of these proteins from mature RENCA macrobead
conditioned media had no impact on survival of DU145/GR cells (Figure 22-24C). This
supports the notion that although these proteins may not be individually involved, other
RENCA macrobead-secreted factors contribute to the observed inhibition of DU145/GR
cells.

Addition of RTN4 eluate to naïve media did not influence survival of RENCA, DU145 or
DU145/GR cells (Figure 22D-F). In contrast, naïve media supplemented with TSP1,
recovered from mature RENCA macrobead conditioned media, decreased RENCA cell
survival with a negligible effect on DU145 or DU145/GR cells (Figure 23D-F). Likewise,
addition of TIMP2 eluate to naïve media decreased RENCA and DU145 but not
DU145/GR cell (Figure 24D-F) survival. It is noted that although TSP1 and TIMP2 can
induce cell-specific growth inhibition, each protein was not able to suppress growth of
target cells to the extent of mature RENCA macrobeads. Therefore, the increased tumor
growth observed following the depletion of the above specific proteins from the
conditioned media of mature RENCA macrobeads and the decreased tumor growth in the
presence of these proteins (especially TIMP2 for both DU145 and RENCA cells) supports
the notion that individual proteins present in the mature RENCA macrobead secretome are
necessary, but not individually sufficient, to achieve maximal growth inhibition of target
tumor cells.
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Figure 22: Mature RENCA macrobead-released RTN4 is necessary, but not
individually sufficient, to achieve the full inhibitory capacity of RENCA
macrobeads. (A, D) RENCA, (B, E) DU145, and (C, F) DU145/GR cells were exposed
to (A-C) RTN4-depleted mature RENCA macrobead conditioned media or (D-F) naïve
media to which RTN4, eluted from immunodepleted media, was added. Surviving cells
were quantified 5 days following incubation with the indicated media by neutral red
assay. X-axis includes (A-C) naïve media (Naïve), Rb IgG depleted (Mock), or proteinspecific depletion (-RTN4) from mature RENCA macrobead conditioned media and (DF) mature RENCA macrobead conditioned media (Mature), Rb IgG added (Naïve), or
protein-specific addition (+RTN4) to naïve media. Y-axis represents the percent
survival relative to Rb IgG (Mock) depleted mature RENCA macrobead conditioned
media (A-C) or Rb IgG added to naïve media (Naïve) (D-F). *p-value < 0.05 relative to
Mock in A-C or Naïve in D-F.
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Figure 23: Mature RENCA macrobead-released TSP1 is necessary, but not
individually sufficient, to achieve the full inhibitory capacity of RENCA
macrobeads. (A, D) RENCA, (B, E) DU145, and (C, F) DU145/GR cells were exposed
to (A-C) TSP1-depleted mature RENCA macrobead conditioned media or (D-F) naïve
media to which TSP1, eluted from immunodepleted media, was added. Surviving cells
were quantified 5 days following incubation with the indicated media by neutral red
assay. X-axis includes (A-C) naïve media (Naïve), Rb IgG depleted (Mock), or proteinspecific depletion (-TSP1) from mature RENCA macrobead conditioned media and (DF) mature RENCA macrobead conditioned media (Mature), Rb IgG added (Naïve), or
protein-specific addition (+TSP1) to naïve media. Y-axis represents the percent survival
relative to Rb IgG (Mock) depleted mature RENCA macrobead conditioned media (AC) or Rb IgG added to naïve media (Naïve) (D-F). *p-value < 0.05 relative to Mock in
A-C or Naïve in D-F.
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Figure 24: Mature RENCA macrobead-released TIMP2 is necessary, but not
individually sufficient, to achieve the full inhibitory capacity of RENCA
macrobeads.
(A, D) RENCA,
(B, E)
DU145, and (C, F) DU145/GR cells were exposed
Figure
24: NEW
VERSION
to (A-C) TIMP2-depleted mature RENCA macrobead conditioned media or (D-F) naïve
media to which TIMP2, eluted from immunodepleted media, was added. Surviving cells
were quantified 5 days following incubation with the indicated media by neutral red
assay. X-axis includes (A-C) naïve media (Naïve), Rb IgG depleted (Mock), or proteinspecific depletion (-TIMP2) from mature RENCA macrobead conditioned media and
(D-F) mature RENCA macrobead conditioned media (Mature), Rb IgG added (Naïve),
or protein-specific addition (+TIMP2) to naïve media. Y-axis represents the percent
survival relative to Rb IgG (Mock) depleted mature RENCA macrobead conditioned
media (A-C) or Rb IgG added to naïve media (Naïve) (D-F). *p-value < 0.05 relative to
Mock in A-C or Naïve in D-F.

79

CHAPTER 4: DISCUSSION
In this work, we provide evidence linking RTN4, TSP1, and TIMP2 with EGF receptor
and MEF2 transcriptional regulation to the cell growth-inhibitory response elicited by
RENCA macrobeads. Taken together, our data supports the idea that factors secreted by
mature RENCA macrobeads activate EGFR and modulate MEF2 expression, particularly
MEF2D, to inhibit cellular proliferation. The data also suggests that RENCA macrobeads
exert their full growth inhibitory effects through additional signaling pathways or other cell
communication mechanisms working in concert.

We used acute isoform-specific knockdown of the mammalian MEF2 gene to demonstrate
that isoforms of this evolutionarily conserved transcription factor, deregulated in various
cancer models, have distinct roles in mediating RENCA macrobead-induced inhibition.
Our results show that exposure of target cells to RENCA macrobeads led to the
upregulation of MEF2D (Figure 3). Moreover, MEF2D-silencing completely abolished the
inhibitory activity of RENCA macrobeads (Figure 4), supporting a tumor suppressive role
for this isoform in RENCA and DU145 cell lines. These results are consistent with data
from other groups indicating that high expression of MEF2D is prognostic of survival in
patients with renal carcinoma [298, 299]. Additionally, copy number loss of this MEF2
isoform was associated with prostate cancer progression [300], supporting the notion that
intentional overexpression of MEF2D could reimpose growth control. In agreement with
this idea, a previous study has demonstrated that exogenous MEF2D expression inhibited
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cell proliferation in a panel of rhabdomyosarcoma cell lines [145]. Furthermore, in our
study, we demonstrated that knockdown of MEF2D in the presence of RENCA macrobeads
restored cell cycle distribution to levels present in actively proliferating cells (naïve media)
(Figure 5-6). This data is in line with previous observations that inhibition of MEF2D
upregulates cell cycle genes, leading to cell cycle reentry [151]. Upstream of the
transcription start site, genes encoding GADD45 and CDKN1A/p21 contain putative
MEF2 recognition elements [139, 144]. We have previously shown that Gadd45 expression
was elevated in RENCA cells treated with RENCA macrobeads [85], identifying a
potential downstream component of RENCA macrobead-induced MEF2D signaling that
regulates cell cycle progression. Moreover, ectopically expressed MEF2D increased p21
expression which correlated with cell cycle arrest [145, 301, 302].

We also observed that RENCA macrobeads repress the endogenous expression
of MEF2b in target RENCA cells. Knockdown of MEF2b in this cell line reduced cell
proliferation and independently promoted S-phase arrest, indicating that MEF2b may have
oncogenic activity in this model system. Recently, MEF2B mutations have been described
in multiple renal cancer subtypes [303] but the impact of these mutations on cancer
pathogenesis and progression has not been studied. Mutations affecting the MEF2B gene
have been noted in ~11% of diffuse large B-cell lymphomas (DLBCLs) [126]. In cell lines
representing

DLBCL,

aberrant

activity

of

MEF2B

directly

contributed

to

lymphomagenesis [122]. Subsequent knockdown of MEF2B downregulated the expression
of the proto-oncogene BCL6 and repressed cell growth [122].
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Although a direct effect on MEF2A expression was not observed in RENCA or DU145
cells following culture with RENCA macrobeads, knockdown of MEF2A limited the
ability of RENCA macrobeads to inhibit the growth of both RENCA and DU145 cells as
well as reduced the percentage of cells accumulating in S-phase, supporting a functional
role for MEF2A in RENCA macrobead-induced inhibition. MEF2A influences the
expression of cell cycle progression and DNA damage response genes in cooperation with
other transcription factors [95]. Members of the MEF2 family bind as homo- and
heterodimers to the appropriate DNA consensus sequence [97]. As a heterodimer, MEF2A
preferentially interacts with MEF2D [304, 305]. As such, the loss of MEF2A could be at
least partly responsible for the observed growth inhibition. Alternatively, RENCA
macrobead regulation of target cell growth could be influenced by MEF2A DNA-binding
activity or protein stability without impacting MEF2A mRNA levels. Previous work has
suggested that post-translational modifications of MEF2A affect DNA-binding [306, 307]
and disrupt MEF2A degradation [308]. Constitutively active MEF2A is associated with
increased expression of the ER stress-induced apoptotic protein, CHOP [152], whose
expression was upregulated in target RENCA cells in response to RENCA macrobeads
[85]. Considering the significance of this isoform to the overall growth inhibitory effect of
RENCA macrobeads, further research is necessary to understand the details by which
MEF2A contributes to growth inhibition.

RENCA macrobead-induced growth regulation is also associated with decreased MEF2C
transcripts in DU145 cells, yet MEF2C-silencing promoted cell growth. Based on TCGA
datasets, MEF2C deletion occurs in a minority of high-grade prostate cancers [309].
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MEF2C degradation has also been described to be necessary for cell proliferation and
efficient progression of the cell cycle through mitosis [147]. Therefore, modulation of
MEF2C expression might not be a mechanism by which RENCA macrobeads regulate cell
proliferation. Since RENCA macrobeads release a large number of proteins and other
signals, it is perhaps not unexpected that some of these factors may contribute to a
proliferative phenotype. However, it is apparent that the activity of such factors, when
present, are offset by antiproliferative signals to net an inhibitory response. Interestingly,
RENCA macrobeads were able to restore inhibition of MEF2C-deficient DU145 cells to
levels similar to NT siRNA treated cells with evidence of cell accumulation in G2/M phase.
This supports the idea that RENCA macrobeads utilize an alternative mechanism to restrict
cell proliferation in the absence of MEF2C, which remains to be explored.

Our studies also support mechanisms of cancer growth regulation that extend beyond the
prevalent notion of inhibiting oncogenic signals to achieve tumor inhibition. Excessive
activation of EGFR is associated with tumor progression and therefore, regulation of this
receptor has been considered a major therapeutic target for cancer treatment. Two classes
of therapeutic agents have been developed: monoclonal antibodies that block the binding
of EGFR activating ligands, and tyrosine kinase inhibitors (TKIs) that reversibly or
irreversibly occupy the ATP binding pocket of EGFR. However, the therapeutic efficacy
of these EGFR inhibitors has been discouraging. Most cancers of epithelial origin express
or overexpress EGFR [310, 311]; yet, only a few types of cancer, such as non-small cell
lung cancer (NSCLC) and KRAS wild-type colorectal cancer, exhibit significant, albeit
transient, effectiveness with these inhibitors of EGFR [312]. Our current study illustrates
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that RENCA macrobeads, despite increasing EGFR expression and phosphorylation,
effectively inhibit the growth of DU145, DU145/GR and MDA-MB-231 cells (Figure 7
and Figure 11). As a cell-based therapy, RENCA macrobeads allow for continuous delivery
of numerous signals into the target cell environment, of which several have been previously
reported to stimulate EGFR [85]. In contrast, studies with EGFR have largely been
performed using fixed concentrations of common EGFR agonists, studied individually, for
a short period of time [313-315], resembling a pulsatile or oscillatory pattern of signaling
dynamics. The intensity and duration of EGFR signaling is critical for the cellular response
and is influenced by multiple factors, including the ligand, ligand concentration, receptor
density, docking state etc. In fact, an early paper that evaluated outcomes in cells that
overexpress EGFR suggested that a continuum of receptor activation dictates growth
responses wherein growth stimulation is associated with intermediate levels of activity
while high activity levels contribute to growth inhibition [169]. Consistent with this notion
and in accordance with our study, Gulli and coauthors demonstrated that physiological
concentrations of EGF, accompanied by a 2-fold increase in EGFR activation, is associated
with cell proliferation while supraphysiological doses of EGF, marked by a 15-fold
upregulation in phosphorylated EGFR inhibited proliferation and biased cells towards
death [167].

Furthermore, increased RENCA macrobead-induced inhibition corresponded with a
sustained increase in EGFR expression and activation, at least in DU145 and MDA-MB231 cells (Figure 8). This is consistent with mechanistic studies of a chemical compound
of marine origin with cytotoxic properties, Aplidinä, which has been evaluated in breast
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cancer cell lines [293] and has been tested as a treatment for unresectable renal cell
carcinoma (APL-B-001-01) [316]

and advanced prostate cancer (NCT00780975).

Prolonged activation and delayed down-regulation of EGFR was shown to be necessary
for Aplidinä to be effective as an anti-tumor agent [293]. Putative negative feedback
normally responsible for the transient nature of EGF-induced EGFR activation, involving
receptor internalization and dephosphorylation, may be lost or impaired with RENCA
macrobeads. Since EGFR agonists induce receptor internalization, variations in receptor
ubiquitination, recycling or degradation of endocytosed receptors could contribute to the
sustained signaling observed in the presence of RENCA macrobeads. In fact, differences
in these aspects of EGFR processing have been reported for a variety of EGFR ligands
[190, 317]. Alternatively, RENCA macrobead signals could reduce recruitment of tyrosine
phosphatases responsible for receptor inactivation. In one such study, depletion of the
protein

tyrosine

phosphatase,

PTP1B,

caused

transient

EGF-induced

EGFR

phosphorylation to become sustained [318]. In the same manner, signals that stabilize
adaptor molecules, such as Grb2, to prevent dephosphorylation of tyrosines on the
cytoplasmic tail of EGFR could dictate the extent to which EGFR signaling is preserved
[319]. Importantly, sustained signaling has been associated with growth control while
transient activation has been linked to proliferation [320-322]. In our studies, RENCA
macrobeads were shown to induce sustained activation of EGFR in both DU145 and MDAMB-231 cells, which was accompanied by growth inhibition and cell accumulation in Sphase (Figure 12).
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Although not as robust as in DU145 or MDA-MB-231 cells, growth inhibition is also
observed in DU145/GR and MCF7 cells, which have either reduced kinase activity or low
levels of EGFR, indicating that the anti-proliferative effects of RENCA macrobeads are
not necessarily unique to cells expressing high levels of functional EGFR, but signaling
through EGFR partially contributes to RENCA macrobead-induced growth inhibition.
RENCA macrobead-induced EGFR activation was transient in DU145/GR cells and nonexistent in MCF7 cells. These cell lines accumulate in G2/M phase, indicating that RENCA
macrobeads can arrest cells at two distinct parts of the cell cycle. Given the variety of
signals released by RENCA macrobeads, the notion of restricting growth through multiple
mechanisms is plausible, but further research is needed to explore RENCA macrobeadmediated growth inhibitory mechanisms in these cell lines. Signaling partners of the p21
gene may be interesting candidates for further evaluation. p21, an inhibitor of cyclin
dependent kinases (CDKs), directly regulates CDK1, CDK2, CDK3, CDK4 and CDK6
activity [323]. Overexpression of p21 usually leads to G1 or G2 arrest by inhibiting CDK
activity [324]. p21 can also directly inhibit DNA synthesis by binding to proliferating cell
nuclear antigen (PCNA), causing cells to arrest in S phase [286]. The expression of p21
can be regulated at the transcriptional, post-transcriptional or post-translational levels by
p53-dependent and p53-independent mechanisms [325]. Insults that damage DNA lead to
activation of p53 and p53-dependent induction of the p21 gene. Expression of p21 can also
be induced by DNA-damaging agents via the ATM/ATR-ERK pathway. In these instances,
activated ERK induces p21 expression in a p53-independent manner [326]. Interestingly,
both DU145 and MDA-MB-231 cells have mutant TP53 genes [327, 328] and appear to
respond to RENCA macrobeads through activation of EGFR upstream of ERK activity. In
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contrast, MCF7 cells with functional p53 [327] exhibit no EGFR activity in response to
RENCA macrobeads, but might be able to induce p21 through p53-dependent mechanisms.

Our work also investigated the possibility of an association between EGFR expression and
RENCA macrobead-mediated MEF2 regulation. We observed that MEF2 activity and
MEF2D expression were substantially higher in cells expressing greater levels of
functional EGFR (i.e. DU145 and MDA-MB-231 cells) while cell lines with nonfunctional EGFR or low-levels of receptor displayed reduced ratios of MEF2 activity or
MEF2D expression (i.e. DU145/GR and MCF7 cells) (Figure 9 and Figure 10). Although
we observed a possible association between EGFR and MEF2, this family of transcription
factors serve as endpoints for multiple signaling pathways. For example, MAPK and
calcium-dependent signaling have been identified as regulators of MEF2 activity [95], both
of which are well known hubs for numerous receptor-mediated signaling pathways. Within
the MAPK signaling cascade that includes ERK, p38 kinase and c-Jun N-terminal kinase
(JNK), ERK signaling downstream of EGFR activation has been described to play a critical
role in the production of MEF2D [329]. In addition, leucine-rich repeat kinase 2 (LRRK2),
a kinase enzyme reported to delay EGFR degradation and enhance ERK activation [330]
directly regulates MEF2 activity [331]. Additional studies using EGFR knockdown and
overexpression constructs in these cell lines as well as analysis of central downstream
components will further clarify the role of this receptor in regulating MEF2 behavior in
response to RENCA macrobeads.
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Lastly, our work identified three specific proteins, RTN4, TSP1 and TIMP2, in conditioned
media of mature RENCA macrobeads that contribute to growth regulation of external
tumor cells. We show that individual depletion of these proteins from RENCA macrobead
conditioned media increases survival of RENCA and DU145 cells (Figures 22-24). We
further demonstrate that addition of TIMP2 to naïve cultures can independently decrease
cell survival of these same cell lines, while TSP1 only reduced RENCA cell survival. We
also demonstrate that RTN4 and TSP1 significantly reduced EGFR activation in RENCA
and DU145 cells but not in the DU145/GR cell line (Figures 13-14). In a complementary
set of experiments, we show that the addition of RTN4 and TSP1 into naive culture media
increases EGFR phosphorylation in the same cell lines. Previous studies have reported the
ability of these proteins to restrict the growth of multiple cancers through diverse
mechanisms. Regulators of EGFR signaling, like RTN4, TSP1, and TIMP2, can modulate
EGFR phosphorylation through physical interactions with the EGFR extracellular domain
or through an intracellular event leading to activation or inactivation of the catalytic
domain. Prior studies indicate that these proteins regulate EGFR activity through an
interaction independent of the ligand binding domain of EGFR [234, 261, 280, 281].
Consistent with these previous studies, we have observed that EGFR blockade using (1)
the chimeric anti-EGFR monoclonal antibody, C225, a research grade biosimilar of the
drug cetuximab, or (2) the 528 monoclonal antibody, successfully blocked EGF-mediated
EGFR phosphorylation but had a negligible effect on RENCA macrobead-mediated EGFR
activation (unpublished data). Moreover, the lack of response observed in DU145/GR cells
suggests that the intracellular kinase function of EGFR needs to be intact to elicit a response
to RENCA macrobead-released RTN4 and TSP1.
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Unexpectedly, we noted a substantial reduction in total EGFR levels upon removal of
RTN4, TSP1 and TIMP2 from RENCA macrobead conditioned media in RENCA and
DU145 cells, suggesting a potential role for these proteins in mediating EGFR stability.
Precedence for RTN4-induced stabilization of proteins has been previously established,
although studies evaluating EGFR have not been performed. For example, RTN4 promoted
clustering and prevented degradation of the ER-localized chaperone, protein disulfide
isomerase, in murine spinal motor neurons [332]. In addition, receptors for TSP1 and
TIMP2 have been described to regulate EGFR trafficking, protract internalization and
reduce EGFR degradation [333, 334] but further studies are necessary to establish whether
these proteins working through their cognate receptors regulate EGFR stability in response
to RENCA macrobeads.

We also identified a novel role for exogenous RTN4, TSP1 and TIMP2 in modulating
MEF2 activity and regulating MEF2 expression. With exception of TSP1 in RENCA cells,
depletion of these proteins from RENCA macrobead conditioned media partially
diminished MEF2 activity (Figure 16-18). Likewise, addition of proteins to naïve media
increased MEF2 activity. We also demonstrated that depletion of RTN4, TSP1 and TIMP2
decreased expression of the MEF2D isoform (Figure 19-21), established to be critical for
RENCA macrobead-mediated inhibition. In the same manner, TIMP2 but not RTN4 or
TSP1 eluates increased MEF2D expression in RENCA and DU145 cells. Overall, our data
underlies an essential role of RTN4, TSP1 and TIMP2 in mediating RENCA macrobeadinduced inhibition.
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The studies presented in this thesis support a mechanism by which RENCA macrobeads,
at least partially, regulate tumor cell growth external to the macrobead. Together, these
data demonstrate that cancer cells can respond to external growth control signals and
provide a rationale for the hypothesis that in order to better control cancer growth, it may
be beneficial to consider tumors as a biological system with dysfunctional, but responsive,
growth regulatory mechanisms. As a group of discrete growth-restricted tumor colonies
that secrete a large number of tumor-inhibitory signals, RENCA macrobeads can be used
as a biological-systems therapeutic to regulate a highly dysregulated cancer system,
simultaneously targeting multiple cancer hallmarks to limit the proliferative potential of
tumor cells. The RENCA macrobead concept expounds upon principles presented by Prehn
[335] whereby the growth of a given tumor may be regulated by biological signals
indicating the presence of a tumor mass, even when that mass is not actually present [335337]. This is based on observations that tumors follow a Gompertzian growth curve that
approach an asymptote, similar to normal organs. In other words, growth is represented by
an early exponential phase followed by decelerated progression as organ systems enlarge
and approach a maximum size whereby some mechanism monitors the ultimate size and
precisely regulates its growth along the typical Gompertzian curve toward an asymptotic
plateau [89, 90, 338-341]. Individual tumor colonies encapsulated within the agarose
matrix of RENCA macrobeads regulate their own growth [1]. That is, tumor colonies reach
a maximal size and maintain a constant size through a balance of growth and death
processes. Within RENCA macrobeads, the equilibrium maintained by the growth and
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death of individual tumor colonies can be viewed as a regulated system, that when applied
to freely growing tumor cells, provides a “systems” approach to the treatment of cancers.

Systems biological approaches to regulate cancer growth are increasingly being recognized
as critical to address the complexities of cancer. To date, the cancer treatment arsenal has
relied on a large array of chemotherapeutics, targeted therapies and immunotherapies; yet,
the success of cancer treatments has been limited by inconsistent therapeutic responses,
drug resistance, and tumor recurrence, stemming from the astounding heterogeneity in
cancers. Recent advances in cancer research, specifically in the field of cancer genomics,
has led to the development of a substantial number of novel therapies. Between 2017-2019,
the U.S. FDA approved 153 new drugs, of which 46 (30%) were indicated for the treatment
of cancers [342-344], illustrating the momentum of these efforts. Despite the initial
responsiveness of cancers to a specific treatment, it is evident that most cancers cannot be
successfully treated exclusively with single-agent therapies [345, 346]. Based on the
potential for additive or synergistic anticancer effects, combination therapies hold
tremendous promise for effective clinical outcomes [346] as evidenced by more than 55
new drug combinations approved for joint use by the FDA in the same time frame [347].
The expansive list of cancer driver genes and mutations [348], the multiple hallmarks of
cancer described by Hanahan and Weinberg [7, 349], the intricacies of signaling networks
[350, 351], and the mutual interactions between cancerous cells and the tumor
microenvironment [352] reinforces the requirement to simultaneously target multiple
cancer dependencies to achieve growth control. The Halifax project, a recent collaboration
of more than 350 researchers globally, similarly supports a “broad-spectrum integrative
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design” for cancer therapy that can collectively impact multiple pathways central to the
development and progression of cancer [353]. It is our view that RENCA macrobeads, as
a complex, non-toxic, biological system, act to provide a multifaceted systems restoration
of normal function and interactions. As such, RENCA macrobeads act not as a precisionmedicine approach to single targets; but rather, can be considered a biological-systems
therapy that reestablishes more normal regulation to a highly dysfunctional and
dysregulated cancer system.

With this mindset, it is our contention that the “war on cancer,” based on the premise of
total eradication of all cancer cells within an individual, may not be the most ideal paradigm
for both scientific investigation and clinical care. Between remission and progression, there
is a middle ground where a patient’s cancer can be controlled and they can live, even thrive,
with the disease. What is now often considered a terminal diagnosis may be able to be
managed as a chronic condition. Like cancer, not long ago, a diagnosis of HIV was
considered an inevitable death sentence [354, 355]. Yet today, the approximately 1.1
million people living with HIV in the United States [356] are treated with once-daily,
combination antiretroviral therapy for the remainder of their lives [357]. These advances
in HIV treatment have transformed the life expectancy, quality of life, and health outcomes
of newly diagnosed HIV-positive individuals. Indeed, as of 2019, the lifespan of a person
living with HIV matched the general population [358-360]. In the same manner, focusing
on cancer as a clinically manageable chronic disease offers hope and a new perspective in
cancer care, with an emphasis on living with a high quality of life.
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Supplementary Figure 1: Characterization of gefitinib-resistant DU145 cell lines.
The DU145/GRS gefitinib-resistant subline was established by culturing parental
DU145 cells with incrementally increasing gefitinib concentrations from 1 μM to 3 μM
over 6 months. A second gefitinib-resistant subline (DU145/GRC) was generated by
continuously culturing parental DU145 cells in high-dose (3 μM) gefitinib. (A)
Assessment of resistance to gefitinib in drug-tolerant and resistant populations, and (B)
sensitivity to 100 ng/mL EGF in the parental DU145 and drug resistant DU145 sublines.
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Supplementary Table 1A: List of mouse primer and probe sequences used for qRT-PCR.
Gene
Name

RefSeq No.

Exon
Location

MEF2a NM_001033713

5-6

MEF2b NM_001045484

2-3

MEF2c

NM_025282

7-9

MEF2d

NM_133665

5-7

Gapdh

Tbp

NM_008084

NM_013684

2-3

4-5

Primer

Probe

5’-AAGTTCTGAGGTGGCAAGC-3’

5’-/56FAM/TGCTGAATC/ZEN/TGTCCTCCGAG
AGTGG/3IABkFQ/-3’

5’-CTGATGCTGACGATTACTTTGAG-3’
5’-ATACTGGAAGAGGCGTTGC-3’
5’-CTAGACCAAAGGAACAGGCA-3’
5’-GTTGCCGTATCCATTCCCT-3’
5’-TGTAACACATAGACCTCCAAGTG-3’
5’-TGACATAGCCATTCCCAACG-3’
5’-GCCAGCACTACAGAGAAACAG-3’
5’-GTGGAGTCATACTGGAACATGTAG-3’
5’-AATGGTGAAGGTCGGTGTG-3’
5’-CCAGAACTGAAAATCAACGCAG-3’
5’-TGTATCTACCGTGAATCTTGGC-3’

5’-/56FAM/AATGTCGCA/ZEN/GTCACAAAGCA
CGC/3IABkFQ/-3’
5’-/56FAM/AGATCTGAC/ZEN/ATCCGGTGCA
GGC/3IABkFQ/-3’
5’-/56FAM/CAGGCTCCA/ZEN/TTAGCACTGTT
GAGGT/3IABkFQ/-3’
5’-/56FAM/TGCAAATGG/ZEN/CAGCCCTGGT
G/3IABkFQ/-3’
5’-/56FAM/ACTTGACCT/ZEN/AAAGACCATTG
CACTTCGT/3IABkFQ/-3’

Supplementary Table 1B: List of human primer and probe sequences used for qRT-PCR.
Gene
Name

RefSeq No.

Exon
Location

MEF2A

NM_005587

13-14

MEF2B NM_001145785

MEF2C

NM_002397

MEF2D NM_001271629

GAPDH

TBP

NM_002046

NM_003194

1-2

3-4

11-12

2-3

5-6

Primer

Probe

5’-GGTTCGGACTTGATGCTGAT-3’

5’-/56FAM/AACCCTGAG/ZEN/ATAACTGCCCT
CCAG/3IABkFQ/-3’

5’-CACCACCTAGGACAAGCAG-3’
5’-GATGCGGGAGATCTGGATT-3’
5’-CCCCTGATCTTCGTGCAG-3’

5’-/56FAM/CATCGTCCC/ZEN/AGGCTGAGTG
GAAT/3IABkFQ/-3’

5’-/56FAM/TGCTGTGTG/ZEN/ACTGTGAGATT
5’-AGATTACGAGGATTATGGATGAACG-3’
GCGC/3IABkFQ/-3’
5’-TGTTGGTGCTGTTGAAGATGA-3’

5’-CTGCACTGGTCAACTGGTAA-3’
5’-CAGTCTACTCATTCGCTCACC-3’
5’-TGTAGTTGAGGTCAATGAAGGG-3’
5’-ACATCGCTCAGACACCATG-3’
5’-CAAGAACTTAGCTGGAAAACCC-3’
5’-GATAAGAGCCACGAACCAC-3’

5’-/56FAM/CTCCCCTTC/ZEN/TCTTCCATGCC
CAC/3IABkFQ/-3’
5’-/56FAM/AAGGTCGGA/ZEN/GTCAACGGAT
TTGGTC/3IABkFQ/-3’
5’-/56FAM/CACAGGAGC/ZEN/CAAGAGTGAA
GAACAGT/3IABkFQ/-3’

Supplementary Table 1: Primer and probe sequences. List of (A) mouse and (B)
human primer and probe sequences used for qRT-PCR.
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Appendix B
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Supplementary Figure 2: MEF2 siRNA induces efficient and isoform-specific in
vitro gene silencing. MEF2 isoform transcript levels were analyzed using Taqman
based qRT-PCR in RENCA cells transiently transfected with two-rounds of 1 µM nontargeting (NT), isoform-specific, or combined expressed MEF2 isoform (MEF2 pool)
siRNA at the beginning (day 0) of the growth inhibition assay and following culture for
5 days in naïve media, or together with young or mature RENCA macrobeads (RMB).
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Supplementary Figure 3: MEF2 siRNA induces efficient and isoform-specific in
vitro gene silencing. MEF2 isoform transcript levels were analyzed using Taqman
based qRT-PCR in DU145 cells transiently transfected with two-rounds of 1 µM nontargeting (NT), isoform-specific, or combined expressed MEF2 isoform (MEF2 pool)
siRNA at the beginning (day 0) of the growth inhibition assay and following culture for
5 days in naïve media, or together with young or mature RENCA macrobeads (RMB).
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5% FBS

5% NCS

0.0
0

Control

Immunodepleted

ELISA

Mock Depleted
(ng/mg)

Immunodepleted
(ng/mg)

Eluate
(ng/mg)

TSP1

10.060 ± 1.801

ND

9.071 ± 1.416

TIMP2

1.218 ± 0.162

ND

1.102 ± 0.204

RTN4

0.463 ± 0.077

ND

0.429 ± 0.098

TSP1

11.816 ± 1.765

ND

10.792 ± 1.433

TIMP2

1.507 ± 0.209

ND

1.465 ± 0.262

RTN4

0.490 ± 0.093

ND

0.442 ± 0.074

Supplementary Table 2: Protein-specific antibodies effectively deplete RTN4,
TSP1 and TIMP2 from mature RENCA macrobead conditioned media. Protein
specific anti-IgG antibodies were incubated with RENCA macrobead cultures (5% NCS
for use with RENCA cells or 5% FBS for use with DU145 and DU145/GR cells) 24
hours prior to immunodepletion using Protein A magnetic beads. Rb IgG was used as a
control (mock depleted). Concentrated media was analyzed by ELISA for RTN4, TSP1
and TIMP2. ND, not detected in tested media. Values represent quantity (ng) of detected
protein relative to total protein (mg).
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